MedMen Enterprises (MMNFQ) 10-Q 2 Feb 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 24, 2022	Jan. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 24, 2022
Document Transition Report	false
Entity File Number	000-56199
Entity Registrant Name	MEDMEN ENTERPRISES INC.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1431779
Entity Address, Address Line One	8740 S Sepulveda Blvd
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90045
City Area Code	(424)
Local Phone Number	330-2082
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		1,308,619,247
Entity Central Index Key	0001776932
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Current Assets:
Cash and Cash Equivalents	$ 15,605,362	$ 10,795,999
Accounts Receivable and Prepaid Expenses	5,415,701	7,539,767
Inventory	13,675,322	10,010,731
Assets Held for Sale	43,611,513	123,158,751
Receivable for Assets Held for Sale	11,500,000	0
Other Assets	10,403,527	9,990,992
Total Current Assets	100,211,425	161,496,240
Operating Lease Right-of-Use Assets	34,275,701	47,649,270
Property and Equipment, Net	57,645,329	64,107,792
Intangible Assets, Net	32,653,134	35,746,114
Goodwill	9,810,049	9,810,049
Other Non-Current Assets	3,879,373	4,414,219
TOTAL ASSETS	238,475,011	323,223,684
Current Liabilities:
Accounts Payable and Accrued Liabilities	42,926,092	38,905,818
Income Taxes Payable	67,472,697	58,646,291
Other Liabilities	16,591,825	16,704,283
Derivative Liabilities	3,642,777	6,749,563
Current Portion of Operating Lease Liabilities	11,897,467	10,925,128
Current Portion of Finance Lease Liabilities	4,294,333	4,061,273
Current Portion of Notes Payable	66,294,249	97,003,922
Liabilities Held for Sale	24,524,988	86,595,102
Total Current Liabilities	237,644,428	319,591,380
Operating Lease Liabilities	40,724,983	50,917,244
Finance Lease Liabilities	27,288,988	26,553,287
Other Non-Current Liabilities	2,846,182	3,082,277
Deferred Tax Liability	38,459,344	35,213,671
Senior Secured Convertible Credit Facility	146,193,049	132,005,663
Notes Payable	74,110,205	74,372,898
TOTAL LIABILITIES	567,267,179	641,736,420
SHAREHOLDERS’ EQUITY:
Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding)	0	0
Subordinate Voting Shares (no par value, unlimited shares authorized, 1,302,129,084 and 1,301,423,950 shares issued and outstanding as of December 24, 2022 and June 25, 2022, respectively)	0	0
Additional Paid-In Capital	1,060,236,631	1,057,228,873
Accumulated Deficit	(913,798,904)	(901,758,875)
Total Equity Attributable to Shareholders of MedMen Enterprises Inc.	146,437,727	155,469,998
Non-Controlling Interest	(475,229,895)	(473,982,734)
TOTAL SHAREHOLDERS’ EQUITY	(328,792,168)	(318,512,736)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 238,475,011	$ 323,223,684

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - shares	Dec. 24, 2022	Jun. 25, 2022	Dec. 25, 2021
Preferred Shares, issued (in shares)	0	0
Preferred Shares, outstanding (in shares)	0	0
Subordinate Voting Shares
Subordinate Voting Shares, issued (in shares)	1,301,423,950		1,302,129,084
Subordinate Voting Shares, outstanding (in shares)	1,301,423,950		1,302,129,084

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Income Statement [Abstract]
Revenue	$ 29,554,100	$ 35,517,161	$ 59,598,153	$ 72,253,065
Cost of Goods Sold	14,501,052	17,637,003	29,601,351	36,986,993
Gross Profit	15,053,048	17,880,158	29,996,802	35,266,072
Operating Expenses:
General and Administrative	18,341,221	31,292,754	36,452,557	63,941,988
Sales and Marketing	551,106	1,007,255	994,897	1,600,479
Depreciation and Amortization	3,477,086	6,379,865	7,423,606	12,203,482
Realized and Unrealized Changes in Fair Value of Contingent Consideration	0	(301,459)	(863,856)	(301,459)
Impairment Expense	5,052,995	0	6,716,906	435,241
Other Operating (Income) Expense	(5,634,350)	630,971	(7,544,063)	2,829,999
Total Operating Expenses	21,788,058	39,009,386	43,180,047	80,709,730
Loss from Operations	(6,735,010)	(21,129,228)	(13,183,245)	(45,443,658)
Non-Operating (Income) Expenses:
Interest Expense	9,686,929	8,077,496	19,739,620	16,249,257
Interest Income	(27,991)	(22,907)	(28,024)	(45,915)
Accretion of Debt Discount and Loan Origination Fees	1,543,896	1,277,827	2,885,912	7,625,298
Change in Fair Value of Derivatives	(3,912,376)	(14,106,370)	(3,106,786)	(16,211,785)
Gain on Extinguishment of Debt	0	0	0	(10,233,607)
Total Non-Operating Expenses	7,290,458	(4,773,954)	19,490,722	(2,616,752)
Loss from Continuing Operations Before Provision for Income Taxes	(14,025,468)	(16,355,274)	(32,673,967)	(42,826,906)
Provision for Income Tax Expense	(1,060,808)	8,137,898	(6,752,886)	(11,554,010)
Net Loss from Continuing Operations	(15,086,276)	(8,217,376)	(39,426,853)	(54,380,916)
Net Income (Loss) from Discontinued Operations, Net of Taxes	(2,255,978)	(12,140,600)	26,132,489	(26,587,091)
Net Income (Loss)	(17,342,254)	(20,357,976)	(13,294,364)	(80,968,007)
Net Loss Attributable to Non-Controlling Interest	(1,134,849)	(1,331,174)	(1,247,161)	(6,611,177)
Net Income (Loss) Attributable to Shareholders of MedMen Enterprises Inc.	$ (16,207,405)	$ (19,026,802)	$ (12,047,203)	$ (74,356,830)
Earnings (Loss) Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. - Basic (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.05)
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. - Diluted (in dollars per share)	(0.01)	(0.01)	(0.03)	(0.05)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. - Basic (in dollars per share)	0	(0.01)	0.01	(0.02)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. - Diluted (in dollars per share)	$ 0	$ (0.01)	$ 0.01	$ (0.02)
Weighted-Average Shares Outstanding - Basic (in shares)	1,301,874,615	1,198,515,279	1,301,767,158	1,070,605,666
Weighted-Average Shares Outstanding - Diluted (in shares)	1,301,874,615	1,198,515,279	4,845,052,067	1,070,605,666

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Total	Subordinate Voting Shares	Additional Paid-In Capital	Accumulated Deficit	TOTAL EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF MEDMEN	Non- Controlling Interest
Beginning balance (in shares) at Jun. 26, 2021		726,866,374
Beginning balance at Jun. 26, 2021	$ (253,633,619)		$ 908,992,686	$ (717,232,706)	$ 191,759,980	$ (445,393,599)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (Loss) Income	(60,610,031)			(55,330,028)	(55,330,028)	(5,280,003)
Controlling Interest Equity Transactions
Redemption of MedMen Corp Redeemable Shares (in shares)		4,054,278
Redemption of MedMen Corp Redeemable Shares	0		1,121,441	374,701	1,496,142	(1,496,142)
Shares Issued for Cash, Net of Fees (in shares)		406,249,973
Shares Issued for Cash, Net of Fees	73,393,745		73,393,745		73,393,745
Shares Issued to Settle Debt and Accrued Interest (in shares)		20,833,333
Shares Issued to Settle Debt and Accrued Interest	4,030,000		4,030,000		4,030,000
Shares Issued to Settle Accounts Payable and Liabilities, (in shares)		4,182,730
Shares Issued to Settle Accounts Payable and Liabilities	700,000		700,000		700,000
Equity Component of Debt - New and Amended	41,388,048		41,388,048		41,388,048
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options (in shares)		8,473,868
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options	0
Shares Issued for Exercise of Warrants (in shares)		8,807,605
Shares Issued for Exercise of Warrants	1,273,679		1,273,679		1,273,679
Shares Issued for Conversion of Debt (in shares)		16,014,665
Shares Issued for Conversion of Debt	2,371,100		2,371,100		2,371,100
Stock Grants for Compensation (in shares)		1,455,415
Stock Grants for Compensation	1,421,400		1,421,400		1,421,400
Deferred Tax Impact On Conversion Feature	(13,057,730)		(13,057,730)		(13,057,730)
Share-Based Compensation	1,682,677		1,682,677		1,682,677
Ending balance (in shares) at Sep. 25, 2021		1,196,938,241
Ending balance at Sep. 25, 2021	(201,040,731)	$ 0	1,023,317,046	(772,188,033)	251,129,013	(452,169,744)
Beginning balance (in shares) at Jun. 26, 2021		726,866,374
Beginning balance at Jun. 26, 2021	(253,633,619)		908,992,686	(717,232,706)	191,759,980	(445,393,599)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (Loss) Income	(80,968,007)
Ending balance (in shares) at Dec. 25, 2021		1,200,119,292
Ending balance at Dec. 25, 2021	(219,330,021)	$ 0	1,025,404,359	(791,208,000)	234,196,359	(453,526,380)
Beginning balance (in shares) at Sep. 25, 2021		1,196,938,241
Beginning balance at Sep. 25, 2021	(201,040,731)	$ 0	1,023,317,046	(772,188,033)	251,129,013	(452,169,744)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (Loss) Income	(20,357,976)			(19,026,802)	(19,026,802)	(1,331,174)
Controlling Interest Equity Transactions
Redemption of MedMen Corp Redeemable Shares (in shares)		84,605
Redemption of MedMen Corp Redeemable Shares	0		18,627	6,835	25,462	(25,462)
Shares Issued for Cash, Net of Fees	0
Shares Issued to Settle Debt and Accrued Interest	0
Shares Issued to Settle Accounts Payable and Liabilities, (in shares)		98,118
Shares Issued to Settle Accounts Payable and Liabilities	15,000		15,000		15,000
Equity Component of Debt - New and Amended	0
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options (in shares)		2,283,972
Shares Issued for Vested Restricted Stock Units and Cashless Exercise of Options	0
Shares Issued for Exercise of Warrants	0
Shares Issued for Conversion of Debt	0
Stock Grants for Compensation (in shares)		714,356
Stock Grants for Compensation	207,494		207,494		207,494
Deferred Tax Impact On Conversion Feature	1,345,580		1,345,580		1,345,580
Share-Based Compensation	500,612		500,612		500,612
Ending balance (in shares) at Dec. 25, 2021		1,200,119,292
Ending balance at Dec. 25, 2021	(219,330,021)	$ 0	1,025,404,359	(791,208,000)	234,196,359	(453,526,380)
Beginning balance (in shares) at Jun. 25, 2022		1,301,423,950
Beginning balance at Jun. 25, 2022	(318,512,736)	$ 0	1,057,228,873	(901,758,875)	155,469,998	(473,982,734)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (Loss) Income	4,047,901			4,160,212	4,160,212	(112,312)
Controlling Interest Equity Transactions
Partner Contributions	37,561			37,561	37,561
Redemption of MedMen Corp Redeemable Shares (in shares)		259,814
Redemption of MedMen Corp Redeemable Shares	0		15,318	(15,318)
Share-Based Compensation	863,685		863,685		863,685
Ending balance (in shares) at Sep. 24, 2022		1,301,683,764
Ending balance at Sep. 24, 2022	(313,563,590)	$ 0	1,058,107,876	(897,576,420)	160,531,456	(474,095,046)
Beginning balance (in shares) at Jun. 25, 2022		1,301,423,950
Beginning balance at Jun. 25, 2022	(318,512,736)	$ 0	1,057,228,873	(901,758,875)	155,469,998	(473,982,734)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (Loss) Income	(13,294,364)
Ending balance (in shares) at Dec. 24, 2022		1,302,129,084
Ending balance at Dec. 24, 2022	(328,792,168)	$ 0	1,060,236,631	(913,798,904)	146,437,727	(475,229,895)
Beginning balance (in shares) at Sep. 24, 2022		1,301,683,764
Beginning balance at Sep. 24, 2022	(313,563,590)	$ 0	1,058,107,876	(897,576,420)	160,531,456	(474,095,046)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (Loss) Income	(17,342,254)			(16,207,405)	(16,207,405)	(1,134,849)
Controlling Interest Equity Transactions
Partner Contributions	0
Redemption of MedMen Corp Redeemable Shares (in shares)		445,320
Redemption of MedMen Corp Redeemable Shares	0		15,079	(15,079)
Share-Based Compensation	2,113,676		2,113,676		2,113,676
Ending balance (in shares) at Dec. 24, 2022		1,302,129,084
Ending balance at Dec. 24, 2022	$ (328,792,168)	$ 0	$ 1,060,236,631	$ (913,798,904)	$ 146,437,727	$ (475,229,895)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss from Continuing Operations	$ (39,426,853)	$ (54,380,916)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Deferred Tax Expense	0	(9,365,019)
Depreciation and Amortization	7,471,055	13,121,707
Non-Cash Operating Lease Costs	6,200,503	8,854,752
Accretion of Debt Discount and Loan Origination Fees	2,885,912	7,625,298
Loss on Disposals of Assets	1,358,820	0
Gain on Lease Terminations	(3,464,947)	0
Accretion of Deferred Gain on Sale of Property	(236,095)	(283,314)
Impairment of Assets	6,716,906	435,241
Realized and Unrealized Changes in Fair Value of Contingent Consideration	863,856	0
Change in Fair Value of Derivative Liabilities	(3,106,786)	(16,211,785)
Gain on Extinguishment of Debt	0	(10,233,610)
Share-Based Compensation	2,977,361	3,812,183
Interest Capitalized to Senior Secured Convertible Debt and Notes Payable	12,319,509	13,008,234
Interest Capitalized to Finance Lease Liabilities	969,427	777,564
Changes in Operating Assets and Liabilities:
Accounts Receivable and Prepaid Expenses	5,057,758	(1,830,219)
Inventory	(3,664,591)	(3,139,817)
Other Current Assets	(412,535)	321,953
Other Assets	534,846	479,019
Accounts Payable and Accrued Liabilities	7,659,848	3,218,996
Interest Payments on Finance Leases	(3,639,574)	(3,510,293)
Cash Payments - Operating Lease Liabilities	(1,501,594)	(5,777,739)
Income Taxes Payable	12,072,079	17,776,242
Other Current Liabilities	(976,314)	(1,282,468)
NET CASH PROVIDED BY (USED IN) CONTINUED OPERATING ACTIVITIES	10,658,591	(36,583,991)
Net Cash Used in Discontinued Operating Activities	(18,992,355)	(13,314,891)
NET CASH USED IN OPERATING ACTIVITIES	(8,333,764)	(49,898,882)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of Property and Equipment	(5,974,346)	(3,974,462)
Additions to Intangible Assets	(30,999)	(486,759)
Proceeds from the Sale of Assets Held for Sale	51,500,000	0
NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES	45,494,655	(4,461,221)
Net Cash Used in Discontinued Investing Activities	0	(3,107,056)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	45,494,655	(7,568,277)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of Subordinate Voting Shares for Cash	0	95,000,000
Payment of Stock Issuance Costs Relating to Private Placement	0	(5,352,505)
Exercise of Warrants for Cash	0	1,273,679
Payment of Debt Issuance Costs Relating to Senior Secured Convertible Credit Facility	0	(2,608,964)
Proceeds from Issuance of Notes Payable	0	5,000,000
Principal Repayments of Notes Payable	(32,388,433)	(152,887)
Principal Repayments of Finance Lease Liability	(666)	(959)
Distributions - Non-Controlling Interest	37,561	0
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(32,351,538)	93,158,364
NET INCREASE IN CASH AND CASH EQUIVALENTS	4,809,353	35,691,206
Cash Included in Assets Held for Sale	0	(275,178)
Cash and Cash Equivalents, Beginning of Period	10,795,999	11,575,868
CASH AND CASH EQUIVALENTS, END OF PERIOD	15,605,352	46,991,896
SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION
Cash Paid for Interest	5,078,605	1,940,280
Non-Cash Investing and Financing Activities:
Net Assets Transferred to Held for Sale	0	4,476,993
Redemption of MedMen Corp Redeemable Shares	705,134	1,521,604
Derivative Liability Incurred on Convertible Facility and Equity Financing	805,590	30,500,000
Conversion of Convertible Debentures	0	2,371,100
Shares Issued to Settle Debt and Lender Fees	0	4,030,000
Shares Issued to Settle Accounts Payable and Liabilities	0	715,000
Equity Component of Debt - New and Amended	0	41,388,047
Deferred Tax Impact on Conversion Feature	$ 0	$ 11,712,150

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Dec. 24, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS MedMen Enterprises Inc. and its subsidiaries over which the company has control (collectively, “MedMen”, the “Company”, “we” or “us”) is a premier cannabis retailer based in the U.S. with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen offers a robust selection of high-quality products, including MedMen-owned brands – MedMen Red and LuxLyte – through its premium retail stores, proprietary delivery service, as well as curbside and in-store pick up. MedMen Buds provides exclusive access to promotions, product drops and content. As of December 24, 2022, the Company operates 23 store locations across California (13), Nevada (3), Illinois (1), Arizona (1), Massachusetts (1), and New York (4). The Company continues to market its assets in New York and thus classifies all assets and liabilities and profit or loss allocable to its operations in the state of New York as discontinued operations. In August 2022, the Company completed the sale of its operations in the state of Florida of which all assets and liabilities and profit or loss allocable to Florida were classified as discontinued operations until the day of sale, on August 22, 2022. Subsequent to August 22, 2022, the remaining post-acquisition assets and liabilities, which is primarily comprised of a current receivable for the portion of the sales proceeds due to us in March 2023, and profit or loss allocable to Florida have been reclassified as continuing operations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 24, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Preparation The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method. In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements have been condensed or omitted in accordance with SEC rules for interim financial information. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended June 25, 2022, as filed with the Securities and Exchange Commission on September 9, 2022 (the “2022 Form 10-K”). Going Concern As of December 24, 2022, the Company had cash and cash equivalents of $15,605,362 and working capital deficit of $137,433,003. The Company has incurred net losses from continuing operations of $15,086,276 and $39,426,853 for the three and six months ended December 24, 2022, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern. The Company plans to continue to fund its operations through the implementation and expansion of its cost savings plan, and various strategic actions, including the successful negotiations of lower costs of occupancy with its master lease landlord and other landlords, divestiture of non-core assets including but not limited to the current asset group held for sale, New York, as well continuing its on-going revenue and vendor strategy of market expansion and retail revenue and gross margin growth. The Company also needs to obtain an extension or a refinancing of its debt-in-default with the secured senior lender. The annual operating plan for fiscal year 2023 estimates the Company will be able to manage ongoing operations. However, its cash needs are significant and not achievable with the current cash flow from operations. If the above strategic actions, for any reason, are inaccessible, it will have a significantly negative effect on the Company’s financial condition. Additionally, management expects to continue to manage the Company’s operating expenses and reduce its projected cash requirements through reduction of its expenses by delaying new store development, permanently or temporarily closing stores that are deemed to be performing below expectations, and/or implementing other restructuring activities. Furthermore, COVID-19 and the impact the global pandemic on the broader retail environment could also have a significant impact on the Company’s financial position, results of operations, equity and or its access to capital and future financing. COVID-19 In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. The Company is continuously addressing the effects of the COVID-19 pandemic, a discussion of which is available in Item 1A “ Risk Factors ” of the 2022 Form 10-K. The company’s operating results continue to be impacted by the COVID-19 pandemic. The overall impact on our business continues to depend on the length of time that the pandemic continues, the impact on consumer purchasing behavior, macro-economic factors such as inflation, and the extent to which it affects our ability to raise capital, and the effect of governmental regulations imposed in response to the pandemic, which all remain uncertain at this time. The Company will continue to implement and evaluate actions to strengthen our financial position and support the continuity of our business and operations. Basis of Consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of December 24, 2022. Significant Accounting Policies The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended December 24, 2022. Earnings (Loss) per Share The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued. Reclassifications Certain amounts reported in the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. In the Note related to Property and Equipment, the Company reclassified $940,000 to increase leasehold improvements and decrease furniture and fixtures. In the Note related to Intangibles, the Company reclassified $1,440,000 and $964,000 to decrease customer relationships and management agreements, along with the related accumulated amortization. In the Condensed Consolidated Balance Sheet, the Company reclassified $3,662,000 between non-controlling interest and accumulated deficit. In addition, the Company reclassified $6,825,000 to decrease its short-term operating lease liabilities and increase its long-term operating lease liabilities. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections. Recently Adopted Accounting Standards In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “ Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) ” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements. Recently Issued Accounting Standards In March 2020, the FASB issued ASU 2020-04, “ Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations. In September 2022, the FASB issued ASU 2022-04, “ Liabilities – Supplier Finance Programs (Subtopic 405-50) ” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

INVENTORY

INVENTORY	6 Months Ended
	Dec. 24, 2022
Inventory Disclosure [Abstract]
INVENTORY	3. INVENTORY The following table provides a summary of total Inventory as of December 24, 2022 and June 25, 2022: December 24, June 25, Raw Materials $ 736,389 $ 521,777 Work-in-Process 956,705 671,541 Finished Goods 11,982,228 8,817,413 Total Inventory $ 13,675,322 $ 10,010,731 During the six months ended December 24, 2022 and December 25, 2021, the Company recognized impairment of nil and $900,000 respectively, to write down inventory to its net realizable value. The Company did not recognize any impairment of inventory during the three months ended December 24, 2022 and December 25, 2021.

ASSETS HELD FOR SALE

ASSETS HELD FOR SALE	6 Months Ended
	Dec. 24, 2022
Assets Held For Sale
ASSETS HELD FOR SALE	4. ASSETS HELD FOR SALE A reconciliation of our assets held for sale is as follows: Discontinued Operations & Other Assets Balance as of June 25, 2022 $ 123,158,751 Ongoing Activities (12,547,238) Proceeds from Sale (1) (67,000,000) Balance as of December 24, 2022 43,611,513 _____________________________________ (1) See “Note 22 – Discontinued Operations” for further information.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Dec. 24, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	5. PROPERTY AND EQUIPMENT. As of December 24, 2022 and June 25, 2022, property and equipment consists of the following: December 24, June 25, Land and Buildings $ 29,933,999 $ 29,933,999 Capital Leases 5,318,516 5,315,625 Furniture and Fixtures 8,651,132 8,776,994 Leasehold Improvements 33,625,888 33,069,524 Equipment and Software 15,972,636 16,897,649 Construction in Progress 4,169,772 6,828,923 Total Property and Equipment 97,671,943 100,822,714 Less Accumulated Depreciation (40,026,614) (36,714,922) Property and Equipment, Net $ 57,645,329 $ 64,107,792 Depreciation expense related to continuing operations for three months ended December 24, 2022 and December 25, 2021 was $3,499,585 and $6,864,790, respectively. Depreciation expense related to continuing operations for six months ended December 24, 2022 and December 25, 2021 was $7,471,055 and $13,121,707, respectively. The amount of depreciation recognized for capital leases during the three months ended December 24, 2022 and December 25, 2021 was $267,312. The amount of depreciation recognized for capital leases during the six months ended December 24, 2022 and December 25, 2021 was $534,624. see “Note 9 – Leases” for further information. Borrowing costs were not capitalized as there were no active construction projects in progress during the three and six months ended December 24, 2022. During the three and six months ended December 25, 2021, borrowing costs totaling $375,241 were capitalized using an average capitalization rate of 11.95%.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Dec. 24, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS As of December 24, 2022 and June 25, 2022, intangible assets consist of the following: December 24, June 25, Dispensary Licenses $ 40,814,762 $ 49,253,452 Customer Relationships 16,409,600 16,409,600 Capitalized Software 7,413,470 7,413,470 Intellectual Property 12,455,287 4,016,597 Total Intangible Assets $ 77,093,119 $ 77,093,119 Dispensary Licenses $ (18,084,368) $ (16,876,912) Customer Relationships (15,378,567) (15,870,284) Capitalized Software (4,824,287) (4,413,974) Intellectual Property (6,152,763) (4,185,835) Less Accumulated Amortization (44,439,985) (41,347,005) Intangible Assets, Net $ 32,653,134 $ 35,746,114 The Company recorded amortization expense related to continuing operations for the three months ended December 24, 2022 and December 25, 2021 of $1,410,858 and $3,206,091, respectively and amortization expense related to continuing operations for the six months ended December 24, 2022 and December 25, 2021 of $3,123,979 and $6,431,928, respectively.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	6 Months Ended
	Dec. 24, 2022
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As of December 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following: December 24, June 25, Accounts Payable $ 19,663,409 $ 14,627,746 Accrued Liabilities 9,862,983 9,464,567 Accrued Inventory 6,397,508 5,868,831 Accrued Payroll 1,405,253 1,682,517 Local & State Taxes Payable 5,030,310 6,695,532 Deferred Gain on Sale of Assets 566,627 566,627 Total Accounts Payable and Accrued Liabilities $ 42,926,090 $ 38,905,820

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	6 Months Ended
	Dec. 24, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	8. DERIVATIVE LIABILITIES A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three and six months ended December 24, 2022 is as follows: TOTAL Balance as of June 25, 2022 $ 6,749,563 Change in Fair Value of Derivative Liabilities (3,106,786) Balance as of December 24, 2022 $ 3,642,777 On August 17, 2021, in connection with the amended and restated senior secured convertible credit facility (the Sixth Amendment”), the Company provided the note holders top-up and preemptive rights which were bifurcated from the related notes and classified as a derivative due to the variability of the number and price of shares issuable under these rights. See “ Note 11 – Senior Secured Convertible Credit Facility” for further information. The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black-Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at December 24, 2022: Top-Up Average Stock Price $ 0.02 Weighted-Average Probability 50.00 % Term (in Years) 5 Expected Stock Price Volatility 121.15 % The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities: Number of Exercise Expiration March 2021 Private Placement (1) 50,000,000 $0.50 March 27, 2024 50,000,000 _____________________________________ (1) See “Note 12 – Shareholders’ Equity” for further information. The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables: Expected Stock Price Volatility 161.95% Risk-Free Annual Interest Rate 2.35% Expected Life (in Years) 0.25 Share Price $0.02 Exercise Price $0.37

LEASES

LEASES	6 Months Ended
	Dec. 24, 2022
Leases [Abstract]
LEASES	9. LEASES The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates. The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended December 24, 2022 and June 25, 2022: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 267,312 $ 251,221 $ 534,624 $ 534,627 Interest on Lease Liabilities 1,835,068 1,725,752 3,639,574 3,510,293 Operating Lease Cost 2,746,638 4,412,675 6,200,503 8,854,752 Total Lease Expenses $ 4,849,018 $ 6,389,648 $ 10,374,701 $ 12,899,672 Sublease Income (1) $ (1,521,651) $ (1,444,234) $ (3,043,302) $ (1,444,234) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ (1,818) $ — $ 666 $ 959 Operating Cash Flows from Operating Leases $ 474,802 $ 2,298,848 $ 1,501,594 $ 5,777,739 _____________________________________ (1) See “Note 16 – Other Operating Income” for further information. The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of December 24, 2022 and June 25, 2022, is as follows: December 24, June 25, Weighted-Average Remaining Lease Term (Years) - Finance Leases 46 46 Weighted-Average Remaining Lease Term (Years) - Operating Leases 7 8 Weighted-Average Discount Rate - Finance Leases 24.81 % 24.33 % Weighted-Average Discount Rate - Operating Leases 16.66 % 18.70 % Future lease payments under non-cancellable operating leases and finance leases as of December 24, 2022 are as follows: Fiscal Year Ending Operating Finance July 1, 2023 (remaining) $ 4,692,026 $ 2,934,524 June 29, 2024 12,931,089 10,961,495 June 28, 2025 9,311,213 7,087,736 June 27, 2026 9,495,658 7,300,368 June 26, 2027 9,466,730 7,519,379 Thereafter 26,267,466 1,061,283,374 Total Lease Payments 72,164,182 1,097,086,876 Less Interest (19,541,732) (1,065,503,555) Lease Liability Recognized $ 52,622,450 $ 31,583,321 The Company entered into a management agreement (the “Management Agreement”) with a third party to operate its cultivation facilities in California and Nevada (the “Cultivation Facilities”). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the “Purchase Option”). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of December 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three and six months ended December 24, 2022, the Company recorded sublease income under the Management Agreement. See “ Note 16 – Other Operating Income ” for further information.
LEASES	9. LEASES The Company has various operating and finance leases for land, buildings, equipment and other assets that are used for corporate purposes as well as for the production and sale of cannabis products. These leases are subject to covenants and restrictions standard to the industry in which the Company operates. The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended December 24, 2022 and June 25, 2022: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 267,312 $ 251,221 $ 534,624 $ 534,627 Interest on Lease Liabilities 1,835,068 1,725,752 3,639,574 3,510,293 Operating Lease Cost 2,746,638 4,412,675 6,200,503 8,854,752 Total Lease Expenses $ 4,849,018 $ 6,389,648 $ 10,374,701 $ 12,899,672 Sublease Income (1) $ (1,521,651) $ (1,444,234) $ (3,043,302) $ (1,444,234) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ (1,818) $ — $ 666 $ 959 Operating Cash Flows from Operating Leases $ 474,802 $ 2,298,848 $ 1,501,594 $ 5,777,739 _____________________________________ (1) See “Note 16 – Other Operating Income” for further information. The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of December 24, 2022 and June 25, 2022, is as follows: December 24, June 25, Weighted-Average Remaining Lease Term (Years) - Finance Leases 46 46 Weighted-Average Remaining Lease Term (Years) - Operating Leases 7 8 Weighted-Average Discount Rate - Finance Leases 24.81 % 24.33 % Weighted-Average Discount Rate - Operating Leases 16.66 % 18.70 % Future lease payments under non-cancellable operating leases and finance leases as of December 24, 2022 are as follows: Fiscal Year Ending Operating Finance July 1, 2023 (remaining) $ 4,692,026 $ 2,934,524 June 29, 2024 12,931,089 10,961,495 June 28, 2025 9,311,213 7,087,736 June 27, 2026 9,495,658 7,300,368 June 26, 2027 9,466,730 7,519,379 Thereafter 26,267,466 1,061,283,374 Total Lease Payments 72,164,182 1,097,086,876 Less Interest (19,541,732) (1,065,503,555) Lease Liability Recognized $ 52,622,450 $ 31,583,321 The Company entered into a management agreement (the “Management Agreement”) with a third party to operate its cultivation facilities in California and Nevada (the “Cultivation Facilities”). On September 30, 2021, the landlord approved the third party to operate the leased facilities which effectuated the Management Agreement. The Management Agreement provides the third party an option to acquire all the assets used in the Cultivation Facilities, including the cannabis licenses and equipment, for $1 (the “Purchase Option”). The fee for the services under the Management Agreement is 100% and 30% of the California and Nevada Cultivation Facilities net revenue, respectively. The term of the Management Agreement remains in effect until the earlier of (a) the closing of any sale pursuant to the Purchase Option and (b) the expiration of the term, as applicable, of the master lease, at which time this Management Agreement shall automatically terminate without any further action of the Parties. As of December 24, 2022, the Management Agreement remains in effect as neither termination condition has occurred. During the three and six months ended December 24, 2022, the Company recorded sublease income under the Management Agreement. See “ Note 16 – Other Operating Income ” for further information.

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Dec. 24, 2022
Notes Payable [Abstract]
NOTES PAYABLE	10. NOTES PAYABLE Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the six months ended December 24, 2022 As of December 24, 2022 and June 25, 2022, notes payable consist of the following: December 24, June 25, Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 72,300,000 $ 72,300,000 Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 66,169,035 97,162,001 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10% per annum and require minimum monthly payments of $15,660 and $18,471. 2,057,207 2,057,207 Other 15,691 15,691 Total Notes Payable 140,541,933 171,534,899 Less Unamortized Debt Issuance Costs and Loan Origination Fees (137,478) (158,079) Net Amount 140,404,455 171,376,820 Less Current Portion of Notes Payable (66,294,249) (97,003,922) Notes Payable, Net of Current Portion $ 74,110,206 $ 74,372,898 A reconciliation of the beginning and ending balances of notes payable for the six months ended December 24, 2022 is as follows: December 24, Balance at Beginning of Period $ 171,376,820 Paid-In-Kind Interest Capitalized 1,257,988 Cash Payments (32,388,433) Accretion of Debt Discount (239,953) Accretion of Debt Discount Included in Discontinued Operations 398,032 Balance at End of Period $ 140,404,454 Less Current Portion of Notes Payable $ (66,294,249) Notes Payable, Net of Current Portion $ 74,110,205 Non-Revolving Senior Secured Term Loan Facility In February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification required that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposed covenants in regard to strategic actions the Company would have to implement if unable to pay the Term Loans by the extended stated maturity date. During the six months ended December 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $31,600,000 with proceeds from the sale. An additional $ 8,500,000 principal repayment will be made in 2023 upon receipt of the final installment payment from the sale of the Company’s Florida-based operations. The Facility and Term Loans remain in default as of December 24, 2022 as the principal balance matured on July 31, 2022 and August 1, 2022, respectively. Beginning in December 2022, the interest assessed on the Facility and Term Loans include a default interest rate of 5%. As of December 24, 2022, the Company is in ongoing discussions with the Lenders. 11. SENIOR SECURED CONVERTIBLE CREDIT FACILITY Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended December 24, 2022. As of December 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following: Tranche December 24, June 25, 2022 Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 1A $ 23,944,485 $ 22,880,556 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 1B 103,124,572 98,542,422 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 2 33,534,018 32,043,996 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 3 12,985,058 12,408,091 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 4 15,273,641 14,594,985 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 24,512,781 23,424,438 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. IA-1 3,428,182 3,275,857 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. IA-2 6,629,552 6,334,980 Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 10,348,746 9,888,919 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 2,292,231 2,190,380 Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 12,893,031 12,320,154 Total Drawn on Senior Secured Convertible Credit Facility 248,966,298 237,904,778 Less Unamortized Debt Discount (102,773,249) (105,899,115) Senior Secured Convertible Credit Facility, Net $ 146,193,049 $ 132,005,663 A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the six months ended December 24, 2022 is as follows: Tranche 1 Tranche 2 Tranche 3 Tranche 4 Incremental Advance Incremental Advance 3rd Advance Amendment Restatement Fee Notes 2nd Restatement Fee TOTAL Balance as of June 25, 2022 $ 80,178,586 $ — $ 21,218,356 $ — $ 8,217,079 $ — $ 1,051,827 $ — $ 224,585 $ — $ 433,598 $ — $ 842,981 $ — $ 15,512,409 $ 2,211,711 $ 2,114,531 $ — $ 132,005,663 $ — Paid-In-Kind Interest Capitalized 5,646,079 1,490,022 576,967 678,656 152,325 294,572 572,878 1,088,344 459,827 101,851 11,061,521 Accretion of Debt Discount 1,954,788 514,561 199,249 — — — — 376,148 73,578 7,541 3,125,865 Balance as of December 24, 2022 $ 87,779,453 $ 23,222,939 $ 8,993,295 $ 1,730,483 $ 376,910 $ 728,170 $ 1,415,859 $ 16,976,901 $ 2,745,116 $ — $ 2,223,923 $ 146,193,049

SENIOR SECURED CONVERTIBLE CRED

SENIOR SECURED CONVERTIBLE CREDIT FACILITY	6 Months Ended
	Dec. 24, 2022
Debt Disclosure [Abstract]
SENIOR SECURED CONVERTIBLE CREDIT FACILITY	10. NOTES PAYABLE Refer to the 2022 Form 10-K for complete disclosure of current terms of notes payable included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the six months ended December 24, 2022 As of December 24, 2022 and June 25, 2022, notes payable consist of the following: December 24, June 25, Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 72,300,000 $ 72,300,000 Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 66,169,035 97,162,001 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10% per annum and require minimum monthly payments of $15,660 and $18,471. 2,057,207 2,057,207 Other 15,691 15,691 Total Notes Payable 140,541,933 171,534,899 Less Unamortized Debt Issuance Costs and Loan Origination Fees (137,478) (158,079) Net Amount 140,404,455 171,376,820 Less Current Portion of Notes Payable (66,294,249) (97,003,922) Notes Payable, Net of Current Portion $ 74,110,206 $ 74,372,898 A reconciliation of the beginning and ending balances of notes payable for the six months ended December 24, 2022 is as follows: December 24, Balance at Beginning of Period $ 171,376,820 Paid-In-Kind Interest Capitalized 1,257,988 Cash Payments (32,388,433) Accretion of Debt Discount (239,953) Accretion of Debt Discount Included in Discontinued Operations 398,032 Balance at End of Period $ 140,404,454 Less Current Portion of Notes Payable $ (66,294,249) Notes Payable, Net of Current Portion $ 74,110,205 Non-Revolving Senior Secured Term Loan Facility In February 2022, the Company executed the Sixth Modification extending the maturity date of the senior secured term loan facility (the “Facility”) with Hankey Capital and Stable Road Capital (the “Lenders”) to July 31, 2022 with respect to the Facility, and August 1, 2022 with respect to the incremental term loans (collectively, the “Term Loans”). The Sixth Modification required that the Company make a mandatory prepayment of at least $37,500,000 in the event the sale of certain assets and imposed covenants in regard to strategic actions the Company would have to implement if unable to pay the Term Loans by the extended stated maturity date. During the six months ended December 24, 2022, in connection with the sale of the Company’s Florida-based operations, the Company made a principal repayment of $31,600,000 with proceeds from the sale. An additional $ 8,500,000 principal repayment will be made in 2023 upon receipt of the final installment payment from the sale of the Company’s Florida-based operations. The Facility and Term Loans remain in default as of December 24, 2022 as the principal balance matured on July 31, 2022 and August 1, 2022, respectively. Beginning in December 2022, the interest assessed on the Facility and Term Loans include a default interest rate of 5%. As of December 24, 2022, the Company is in ongoing discussions with the Lenders. 11. SENIOR SECURED CONVERTIBLE CREDIT FACILITY Refer to the 2022 Form 10-K for complete disclosure of current terms of the senior secured convertible facility included in the footnotes of the annual financial statements as of June 25, 2022. There were no amendments during the three months ended December 24, 2022. As of December 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following: Tranche December 24, June 25, 2022 Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 1A $ 23,944,485 $ 22,880,556 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 1B 103,124,572 98,542,422 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 2 33,534,018 32,043,996 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 3 12,985,058 12,408,091 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 4 15,273,641 14,594,985 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 24,512,781 23,424,438 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. IA-1 3,428,182 3,275,857 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. IA-2 6,629,552 6,334,980 Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 10,348,746 9,888,919 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 2,292,231 2,190,380 Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 12,893,031 12,320,154 Total Drawn on Senior Secured Convertible Credit Facility 248,966,298 237,904,778 Less Unamortized Debt Discount (102,773,249) (105,899,115) Senior Secured Convertible Credit Facility, Net $ 146,193,049 $ 132,005,663 A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the six months ended December 24, 2022 is as follows: Tranche 1 Tranche 2 Tranche 3 Tranche 4 Incremental Advance Incremental Advance 3rd Advance Amendment Restatement Fee Notes 2nd Restatement Fee TOTAL Balance as of June 25, 2022 $ 80,178,586 $ — $ 21,218,356 $ — $ 8,217,079 $ — $ 1,051,827 $ — $ 224,585 $ — $ 433,598 $ — $ 842,981 $ — $ 15,512,409 $ 2,211,711 $ 2,114,531 $ — $ 132,005,663 $ — Paid-In-Kind Interest Capitalized 5,646,079 1,490,022 576,967 678,656 152,325 294,572 572,878 1,088,344 459,827 101,851 11,061,521 Accretion of Debt Discount 1,954,788 514,561 199,249 — — — — 376,148 73,578 7,541 3,125,865 Balance as of December 24, 2022 $ 87,779,453 $ 23,222,939 $ 8,993,295 $ 1,730,483 $ 376,910 $ 728,170 $ 1,415,859 $ 16,976,901 $ 2,745,116 $ — $ 2,223,923 $ 146,193,049

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	6 Months Ended
	Dec. 24, 2022
Equity [Abstract]
SHAREHOLDERS’ EQUITY	12. SHAREHOLDERS’ EQUITY Issued and Outstanding A reconciliation of the beginning and ending issued and outstanding shares is as follows: Subordinate MM CAN USA MM Enterprises USA Balance as of June 25, 2022 1,301,423,950 65,066,106 725,016 Redemption of MedMen Corp Redeemable Shares 259,814 (259,814) — Balance as of September 24, 2022 1,301,683,764 64,806,292 725,016 Redemption of MedMen Corp Redeemable Shares 445,320 (445,320) — Balance as of December 24, 2022 1,302,129,084 64,360,972 725,016 Non-Controlling Interests Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of December 24, 2022 and June 25, 2022, the holders of the MM CAN USA Redeemable Shares represent approximately 4.71% and 4.76%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately 0.05% of the Company. Variable Interest Entities The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of Venice Caregiver Foundation, Inc., LAX Fund II Group, LLC, and Natures Cure, Inc. This information represents amounts before intercompany eliminations. As of and for the six months ended December 24, 2022, the balances and activities attributable to the VIEs consist of the following: Venice Caregivers LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,471,651 $ — $ 27,171,414 $ 28,643,065 Non-Current Assets 8,482,483 3,011,882 4,874,353 16,368,718 Total Assets $ 9,954,134 $ 3,011,882 $ 32,045,767 $ 45,011,783 Current Liabilities $ 10,984,598 $ 16,687,993 $ 10,031,350 $ 37,703,941 Non-Current Liabilities 6,957,566 1,922,553 1,342,632 10,222,751 Total Liabilities $ 17,942,164 $ 18,610,546 $ 11,373,982 $ 47,926,692 Non-Controlling Interest $ (7,988,030) $ (15,598,664) $ 20,671,785 $ (2,914,909) Revenues $ 3,766,847 $ — $ 6,562,185 $ 10,329,032 Net (Loss) Income Attributable to Non-Controlling Interest $ (944,589) $ (1,622,510) $ 1,917,227 $ (649,872) As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following: Venice Caregivers LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,735,304 $ 1,067,636 $ 23,557,168 $ 26,360,108 Non-Current Assets 10,073,880 3,379,412 4,973,459 18,426,751 Total Assets $ 11,809,184 $ — $ 4,447,048 $ — $ 28,530,627 $ 44,786,859 Current Liabilities $ 9,238,460 $ 16,238,249 $ 8,433,436 $ 33,910,145 Non-Current Liabilities 9,614,164 2,184,953 1,342,633 13,141,750 Total Liabilities $ 18,852,624 $ — $ 18,423,202 $ — $ 9,776,069 $ 47,051,895 Non-Controlling Interest $ (7,043,440) $ — $ (13,976,154) $ — $ 18,754,558 $ — $ (2,265,036) Revenues $ 4,815,688 $ — $ 8,816,113 $ 13,631,801 Net (Loss) Income Attributable to Non-Controlling Interest $ (607,858) $ (2,206,450) $ 3,911,125 $ 1,096,817 The net change in the consolidated VIEs and other non-controlling interest are as follows for the six months ended December 24, 2022: Venice Caregivers LAX Fund II Group, LLC Natures Cure, Inc. Other Non- Controlling TOTAL Balance as of June 25, 2022 $ (7,043,440) $ (13,976,154) $ 18,754,558 $ (471,717,698) $ (473,982,734) Net (Loss) Income $ (944,589) $ (1,622,510) $ 1,917,227 $ (597,289) $ (1,247,161) Balance as of December 24, 2022 $ (7,988,029) $ (15,598,664) $ 20,671,785 $ (472,314,987) $ (475,229,895)

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
	Dec. 24, 2022
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	13. SHARE-BASED COMPENSATION The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock units (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative expenses. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, cancelled, expire unexercised, are settled in cash or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in absence of a Compensation Committee. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after 5 or 10 years. A summary of share-based compensation expense for the three and six months ended December 24, 2022 and December 25, 2021 is as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Stock Options $ 1,912,792 $ 97,746 $ 2,625,581 $ 1,314,193 Stock Grants for Compensation — 207,494 — 540,827 Restricted Stock Grants 200,884 402,866 351,780 1,957,163 Total Share-Based Compensation $ 2,113,676 $ 708,106 $ 2,977,361 $ 3,812,183 Stock Options A reconciliation of the beginning and ending balance of stock options outstanding is as follows: Number of Weighted-Average Outstanding at June 25, 2022 8,649,673 $ 1.35 Granted 92,382,965 0.05 Forfeited (312,032) 3.60 Outstanding at December 24, 2022 100,720,606 $ 0.15 Stock Options Exercisable as of December 24, 2022 8,037,095 Long-Term Incentive Plan (“LTIP”) Units and LLC Redeemable Units A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows: LTIP Units LLC Weighted Issued and Balance as of June 25, 2022 and December 24, 2022 19,323,878 725,016 $ 0.52 Restricted Stock Units A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows: Issued and Vested Weighted-Average Balance as of June 25, 2022 10,998,483 4,030,460 $ 0.20 Granted — — — Vested — 490,661 0.21 Forfeited (1) (1,813,408) — (0.22) Non-vested at December 24, 2022 9,185,075 4,521,121 $ 0.30 _____________________________________ (1) Restricted stock units represent units forfeited upon resignation of certain employees prior to their vesting. Warrants A reconciliation of the beginning and ending balance of warrants outstanding is as follows: Number of Warrants Outstanding Subordinate MM CAN USA TOTAL Weighted-Average Balance as of June 25, 2022 352,704,355 97,430,456 450,134,811 $ 0.25 Expired (6,023,696) — (6,023,696) $ 2.03 Balance as of December 24, 2022 346,680,659 97,430,456 444,111,115 $ 0.22

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Dec. 24, 2022
Earnings Per Share [Abstract]
LOSS PER SHARE	14. LOSS PER SHARE The following is a reconciliation for the calculation of basic and diluted loss per share for the three and six months ended December 24, 2022 and December 25, 2021 is as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (15,086) $ (8,217) $ (39,427) $ (54,381) Net Income (Loss) from Discontinued Operations (2,256) (12,141) 26,132 (26,587) Total Loss $ (17,342) $ (20,358) $ (13,294) $ (80,968) Denominator: Weighted-Average Shares Outstanding - Basic 1,301,874,615 1,198,515,279 1,301,767,158 1,070,605,666 Dilutive effect of LTIP and LLC Redeemable Units issued for compensation 19,323,878 19,323,878 19,323,878 19,323,878 Dilutive effect of restricted stock granted under the Equity Plan 9,185,075 25,673,720 9,185,075 25,673,720 Dilutive effect of warrants and top-up warrants 194,720,261 138,498,284 258,878,685 175,668,177 Dilutive effect of convertible debentures 3,255,897,270 1,007,089,116 3,255,897,270 1,007,089,116 Weighted-Average Shares Outstanding - Diluted (1) 4,781,001,100 2,389,100,278 4,845,052,067 2,298,360,557

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	6 Months Ended
	Dec. 24, 2022
General And Administrative Expenses
GENERAL AND ADMINISTRATIVE EXPENSES	15. GENERAL AND ADMINISTRATIVE EXPENSES During the three and six months ended December 24, 2022 and December 25, 2021, general and administrative expenses consisted of the following: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Salaries and Benefits $ 6,536,411 $ 9,991,545 $ 13,468,859 $ 19,903,033 Professional Fees 2,137,010 7,815,185 3,509,420 15,245,844 Rent 3,021,217 4,712,476 6,649,162 9,467,359 Licenses, Fees and Taxes 1,823,436 1,293,194 3,866,945 3,830,982 Share-Based Compensation 2,113,676 722,802 2,977,361 2,370,111 Deal Costs — 1,174,357 429,272 2,811,944 Other General and Administrative 2,709,471 5,583,195 5,551,538 10,312,715 Total General and Administrative Expenses $ 18,341,221 $ 31,292,754 $ 36,452,557 $ 63,941,988

OTHER OPERATING (INCOME) EXPENS

OTHER OPERATING (INCOME) EXPENSE	6 Months Ended
	Dec. 24, 2022
Other Operating Income Expense
OTHER OPERATING (INCOME) EXPENSE	16. OTHER OPERATING (INCOME) EXPENSE During the three and six months ended December 24, 2022 and December 25, 2021 , other operating (income) expense consisted of the following: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Other Operating (Income) Expense: Loss (Gain) on Disposals of Assets $ 1,153,225 $ (141,662) $ 1,358,820 $ (126,516) Restructuring and Reorganization Expense — 385,652 423,793 2,764,327 Gain on Settlement of Accounts Payable 215,659 — 141,022 (177,990) (Gain) Loss on Lease Terminations (1,877,298) 173,765 (3,464,947) 173,765 (Gain) Loss on Disposal of Assets Held for Sale (112,225) — 532,598 — Legal Settlements (3,491,431) — (3,491,431) — Other Income (1,522,280) 213,216 (3,043,918) 196,413 Total Other Operating (Income) Expense $ (5,634,350) $ 630,971 $ (7,544,063) $ 2,829,999 During the three and six months ended December 24, 2022 , the Company recorded $1,521,651 and $3,043,302, respectively of sublease income related to the cultivation facilities in California and Nevada as a component of Other Operating Income in the Consolidated Statements of Operations.

PROVISION FOR INCOME TAXES AND

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES	6 Months Ended
	Dec. 24, 2022
Income Tax Disclosure [Abstract]
PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES	17. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES The following table summarizes the Company’s income tax expense and effective tax rates for the three and six months ended December 24, 2022 and December 25, 2021 Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Loss from Continuing Operations Before Provision for Income Taxes $ (14,025,468) $ (16,355,274) $ (32,673,967) $ (42,826,906) Provision for Income Tax Expense (1,060,808) 8,137,898 (6,752,886) (11,554,010) Effective Tax Rate 8 % -50 % 21 % 27 % We have historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate (“AETR”) for the full fiscal year to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. For the three and six months ended December 25, 2021 , we determined we could no longer reliably estimate income taxes utilizing an AETR. The AETR estimate is highly sensitive to estimates of ordinary income (loss) and permanent differences such that minor fluctuations in these estimates could result in significant fluctuations of the Company’s AETR. Accordingly, we used our actual year-to-date effective tax rate to calculate income taxes for the three and six months ended December 24, 2022 . As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Massachusetts state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns. The Company has approximately gross $12,230,000 (tax effected $3,240,000) of Canadian non-capital losses and $6,000,000 (tax effected $1,620,000) of share issuance cost 20(1)(e) balance. The loss tax attribute has been determined to be more likely than not that the tax attribute would not yield any tax benefit. As such, the Company has recorded a full valuation allowance against the benefit. Since IRC Section 280E was not applied in the California Franchise Tax Returns, the Company has approximately $22,000,000 of gross California net operating losses which begin expiring in 2033 as of June 25, 2022. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $217,300,000 will not be realized. The effective tax rate for the three and six months ended December 24, 2022 is different from the three months ended September 25, 2021, respectively, primarily due to the Company’s income and related 280E expenditures. The Company’s non-deductible expenses related to IRC Section 280E limitations have remained relatively consistent. The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and in Canada. The Company is generally subject to audit by taxing authorities in various U.S., state, and in foreign jurisdictions for fiscal years 2014 through the current fiscal year. As of December 24, 2022, the Company had $18,781,424 of unrecognized tax benefits, all of which would reduce income tax expense and the effective tax rate if recognized. During the three and six months ended December 24, 2022, the Company recognized a net discrete tax expense of $407,993 primarily related on interest of past liabilities. During the next twelve months, the Company does not estimate any material reduction in its unrecognized tax benefits.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 24, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	18. COMMITMENTS AND CONTINGENCIES Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of December 24, 2022 and June 25, 2022, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future. Claims and Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. The Company recognizes legal settlement expense when litigation losses related to pending or threatening lawsuits could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. The Company recognizes legal settlement gains when a favorable settlement is awarded to the Company and payment is received. Gain and losses related to claims and litigation are recorded as a component of Other Operating (Income) Expense in the Condensed Consolidated Financial Statements. As of December 24, 2022, there are also no proceedings in which any of the Company’s current directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest. In March 2020, litigation was filed against the Company in the Superior Court of Arizona, Maricopa County, related to a purchase agreement for a previous acquisition. The Superior Court of Arizona, Maricopa County granted summary judgement in favor of the Company on all counts in July 2022. The Company is currently in process of recovering certain fees and costs associated with the lawsuit from the plaintiffs, and the plaintiffs have filed an appeal of the summary judgment decision. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements. In April 2020, a complaint was filed against the Company in Los Angeles Superior Court related to a contemplated acquisition in which the plaintiffs are seeking damages for alleged breach of contract and breach of implied covenant of good faith and fair dealing seeking declaratory relief and specific performance. The Company filed counterclaims including for breach of contract, breach of promissory note, unjust enrichment and declaratory relief. After the end of the quarter ending December 24, 2022, the parties reached a tentative agreement to resolve the litigation; however, the probable loss to the Company cannot be reasonably estimated. As such, no amount has been accrued in these financial statements. In November 2020, entities affiliated with former officers of the Company initiated arbitration against a subsidiary of the Company in Los Angeles, California asserting breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, and unjust enrichment. The claimants are generally seeking damages and compensatory damages according to proof, including lost earnings and other benefits, past and future, interest on lost earnings and benefits, reasonable attorney’s fees, and such other and further relief as the court deems proper. The Company asserted counterclaims, including for breach of the same management agreements. The arbitration hearing has been rescheduled and the matter is being disputed. The litigation remains at an early stage and the likelihood of a loss contingency is remote. As such, no amount has been accrued in these financial statements. In October 2021, a suit for premises liability and negligence seeking unspecified damages for pain and suffering, disability, mental and emotional distress, and loss of earnings was filed against the Company in Los Angeles Superior Court. The matter is in the process of being litigated. The Company believes the likelihood of loss is remote. As such, no amount has been accrued in these financial statements. In July 2022, a complaint was filed in Los Angeles Superior Court by Baker & McKenzie LLP, a former law firm to the Company, seeking in excess of $600,000 in legal fees plus accrued interest. The Company has filed a counterclaim against Baker & McKenzie claiming overbilling on total invoices propounded by the law firm to the Company exceeding $18,500,000. The litigation remains at an early stage and the likelihood of a loss contingency is remote. As such, no amount has been accrued in these financial statements The Company is the defendant in several complaints filed by various of its landlords seeking rents and damages under lease arrangements. First, in 2020 a complaint was filed in Cook County Circuit Court, Illinois against the Company by a landlord claiming the Company had failed to meet its obligations to apply effort to obtain a retail cannabis license at a property, for which the landlord is seeking rents and damages. Plaintiff has filed a motion for summary judgment which remains pending. If the litigation is not settled or resolved, trial will likely take place during the fiscal year ended 2023 or possibly the fiscal year ended 2024. This matter is preliminary and the Company believes the likelihood of loss is remote. As such, no amount has been accrued in these financial statements. Second, in July 2022, a complaint was filed against the Company in the United States District Court for the Southern District of New York by a landlord seeking damages under a lease on real estate located in Illinois. The Company filed an answer to the complaint arguing that the subject matter of the

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 24, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	19. RELATED PARTY TRANSACTIONS The Company’s Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Dec. 24, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	20. SEGMENT INFORMATION The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker manages the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.

REVENUE

REVENUE	6 Months Ended
	Dec. 24, 2022
Revenue from Contract with Customer [Abstract]
REVENUE	21. REVENUE While the Company operates in one segment as disclosed in “ Note 20 – Segment Information ”, the Company is disaggregating its revenue by geographical region in accordance with ASC 606, “ Revenue from Contracts with Customers ”. Revenue by state for the periods presented are as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, California $ 19,575,393 $ 23,368,439 $ 39,504,378 $ 47,994,994 Nevada 2,812,902 3,855,371 5,810,371 7,934,522 Illinois 3,082,089 4,104,970 6,624,159 8,433,572 Arizona 3,343,592 4,173,609 6,138,238 7,875,206 Massachusetts 734,394 14,772 1,515,277 14,771 Revenue from Continuing Operations 29,548,370 35,517,161 59,592,423 72,253,065 Revenue from Discontinued Operations 2,282,288 8,065,341 5,911,927 15,405,440 Total Revenue $ 31,830,658 $ 43,582,502 $ 65,504,350 $ 87,658,505

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Dec. 24, 2022
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	22. DISCONTINUED OPERATIONS The operating results of the discontinued operations are summarized as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Revenue $ 2,282,288 $ 8,065,341 $ 5,911,927 $ 15,405,440 Cost of Goods Sold 439,466 5,672,043 2,630,135 10,899,596 Gross Profit 1,842,822 2,393,298 3,281,792 4,505,844 Expenses: General and Administrative 2,134,342 6,329,144 6,853,135 11,946,739 Sales and Marketing 15,015 127,844 58,326 231,647 Depreciation and Amortization 21,107 1,189,331 894,002 2,411,090 Impairment Expense — — (78,433) — Gain on Disposal of Assets and Other Income — — (36,305,166) (597,591) Total (Income) Expenses $ 2,170,464 $ 7,646,319 $ (28,578,136) $ 13,991,885 Income (Loss) from Discontinued Operations (327,642) (5,253,021) 31,859,928 (9,486,041) Other Expense: Interest Expense 1,783,685 4,755,126 5,545,446 9,371,955 Accretion of Debt Discount and Loan Origination Fees — 3,446,949 398,032 6,987,857 Total Other Expense 1,783,685 8,202,075 5,943,478 16,359,812 Income (Loss) from Discontinued Operations Before Provision for Income Taxes (2,111,327) (13,455,096) 25,916,450 (25,845,853) Provision for Income Tax Benefit (Expense) (144,651) 1,314,496 216,039 (741,238) Net Income (Loss) from Discontinued Operations $ (2,255,978) $ (12,140,600) $ 26,132,489 $ (26,587,091) The carrying amounts of assets and liabilities in the disposal group are summarized as follows: December 24, June 25, Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents $ 540,828 $ 1,124,076 Restricted Cash 5,280 5,280 Accounts Receivable and Prepaid Expenses 22,019 334,621 Inventory 4,483,051 6,866,833 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 9,569,610 41,273,597 Operating Lease Right-of-Use Assets 19,111,359 31,543,058 Intangible Assets, Net 10,582,559 40,799,146 Other Assets 458,383 1,181,795 TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE 44,773,089 123,128,406 Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities $ 979,864 $ 6,295,745 Income Taxes Payable 389,677 1,671,380 Other Current Liabilities (5,641) 89,069 Current Portion of Operating Lease Liabilities 2,812,765 4,209,512 Current Portion of Finance Lease Liabilities — 174,000 TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 18,398,345 56,410,071 Deferred Tax Liabilities 5,977,580 6,097,597 Notes Payable — 11,100,000 TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 28,552,590 $ 86,047,374

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 24, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	23. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date these Condensed Consolidated Financial Statements were issued and has concluded that no subsequent events have occurred that would require recognition in the Condensed Consolidated Financial Statements or disclosure in the Notes to the Condensed Consolidated Financial Statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 24, 2022
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The accompanying Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method. In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial position of the Company as of and for the interim periods presented have been included. The accompanying Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to our ability to continue as a going concern.
Going Concern	Going Concern As of December 24, 2022, the Company had cash and cash equivalents of $15,605,362 and working capital deficit of $137,433,003. The Company has incurred net losses from continuing operations of $15,086,276 and $39,426,853 for the three and six months ended December 24, 2022, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these Condensed Consolidated Financial Statements, and therefore, to continue as a going concern.
COVID-19	COVID-19 In response to the COVID-19 pandemic, governmental authorities have enacted and implemented various recommendations and safety measures in an attempt to limit the spread and magnitude of the pandemic. The Company is continuously addressing the effects of the COVID-19 pandemic, a discussion of which is available in Item 1A “ Risk Factors ” of the 2022 Form 10-K. The company’s operating results continue to be impacted by the COVID-19 pandemic. The overall impact on our business continues to depend on the length of time that the pandemic continues, the impact on consumer purchasing behavior, macro-economic factors such as inflation, and the extent to which it affects our ability to raise capital, and the effect of governmental regulations imposed in response to the pandemic, which all remain uncertain at this time. The Company will continue to implement and evaluate actions to strengthen our financial position and support the continuity of our business and operations.
Basis of Consolidation	Basis of ConsolidationSubsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. With the exception of MME Florida, LLC, which the Company disposed on August 22, 2022, the list of the Company’s subsidiaries included in the Company’s 2022 Form 10-K remain complete as of December 24, 2022.
Significant Accounting Policies	Significant Accounting Policies The significant accounting policies and critical estimates applied by the Company in these Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in the Company’s 2022 Form 10-K, unless otherwise disclosed in these accompanying notes to the Condensed Consolidated Financial Statements for the interim period ended December 24, 2022.
Earnings (Loss) per Share	Earnings (Loss) per Share The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, restricted stock units, warrants and stock options issued.
Reclassifications	Reclassifications Certain amounts reported in the Condensed Consolidated Financial Statements as of June 25, 2022 have non-material corrections and reclassified in order to conform to the current reporting period presentation. In the Note related to Property and Equipment, the Company reclassified $940,000 to increase leasehold improvements and decrease furniture and fixtures. In the Note related to Intangibles, the Company reclassified $1,440,000 and $964,000 to decrease customer relationships and management agreements, along with the related accumulated amortization. In the Condensed Consolidated Balance Sheet, the Company reclassified $3,662,000 between non-controlling interest and accumulated deficit. In addition, the Company reclassified $6,825,000 to decrease its short-term operating lease liabilities and increase its long-term operating lease liabilities. There was no change to total current assets, total assets, total liabilities, total shareholders’ equity or cash flows as a result of these reclassifications and non-material corrections.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In May 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-04, “ Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) ” (“ASU 2021-04”), which amends existing guidance for earnings per share (“EPS”) in accordance with Topic 260. ASU 2021-04 is effective prospectively for fiscal years beginning after December 15, 2021. The Company adopted ASU 2021-04 on June 26, 2022. The adoption of the standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements. Recently Issued Accounting Standards In March 2020, the FASB issued ASU 2020-04, “ Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ” (“ASU 2020-04”), provides optional expedients and exceptions for applying GAAP to debt instruments, derivatives, and other contracts that reference London Interbank Offered Rate (“LIBOR”) or other reference rates expected to be discontinued as a result of reference rate reform. This guidance is optional and may be elected through December 31, 2022 using a prospective application on all eligible contract modifications. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to instruments affected by reference rate reform if certain criteria are met. The Company did not modify any material contracts due to reference rate reform during the nine months ended September 30, 2022. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations. In September 2022, the FASB issued ASU 2022-04, “ Liabilities – Supplier Finance Programs (Subtopic 405-50) ” (“ASU 2022-04”), which is intended to enhance transparency with supplier finance programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Adoption is applied on a retrospective approach. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its financial position and results of operations.

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Dec. 24, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	The following table provides a summary of total Inventory as of December 24, 2022 and June 25, 2022: December 24, June 25, Raw Materials $ 736,389 $ 521,777 Work-in-Process 956,705 671,541 Finished Goods 11,982,228 8,817,413 Total Inventory $ 13,675,322 $ 10,010,731

ASSETS HELD FOR SALE (Tables)

ASSETS HELD FOR SALE (Tables)	6 Months Ended
	Dec. 24, 2022
Assets Held For Sale
Schedule of Asset Held for Sale	Discontinued Operations & Other Assets Balance as of June 25, 2022 $ 123,158,751 Ongoing Activities (12,547,238) Proceeds from Sale (1) (67,000,000) Balance as of December 24, 2022 43,611,513 _____________________________________ (1) See “Note 22 – Discontinued Operations” for further information.

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Dec. 24, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	As of December 24, 2022 and June 25, 2022, property and equipment consists of the following: December 24, June 25, Land and Buildings $ 29,933,999 $ 29,933,999 Capital Leases 5,318,516 5,315,625 Furniture and Fixtures 8,651,132 8,776,994 Leasehold Improvements 33,625,888 33,069,524 Equipment and Software 15,972,636 16,897,649 Construction in Progress 4,169,772 6,828,923 Total Property and Equipment 97,671,943 100,822,714 Less Accumulated Depreciation (40,026,614) (36,714,922) Property and Equipment, Net $ 57,645,329 $ 64,107,792

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Dec. 24, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	As of December 24, 2022 and June 25, 2022, intangible assets consist of the following: December 24, June 25, Dispensary Licenses $ 40,814,762 $ 49,253,452 Customer Relationships 16,409,600 16,409,600 Capitalized Software 7,413,470 7,413,470 Intellectual Property 12,455,287 4,016,597 Total Intangible Assets $ 77,093,119 $ 77,093,119 Dispensary Licenses $ (18,084,368) $ (16,876,912) Customer Relationships (15,378,567) (15,870,284) Capitalized Software (4,824,287) (4,413,974) Intellectual Property (6,152,763) (4,185,835) Less Accumulated Amortization (44,439,985) (41,347,005) Intangible Assets, Net $ 32,653,134 $ 35,746,114

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	6 Months Ended
	Dec. 24, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	As of December 24, 2022 and June 25, 2022, accounts payable and accrued liabilities consist of the following: December 24, June 25, Accounts Payable $ 19,663,409 $ 14,627,746 Accrued Liabilities 9,862,983 9,464,567 Accrued Inventory 6,397,508 5,868,831 Accrued Payroll 1,405,253 1,682,517 Local & State Taxes Payable 5,030,310 6,695,532 Deferred Gain on Sale of Assets 566,627 566,627 Total Accounts Payable and Accrued Liabilities $ 42,926,090 $ 38,905,820

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	6 Months Ended
	Dec. 24, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liabilities	A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the three and six months ended December 24, 2022 is as follows: TOTAL Balance as of June 25, 2022 $ 6,749,563 Change in Fair Value of Derivative Liabilities (3,106,786) Balance as of December 24, 2022 $ 3,642,777
Schedule of Assumptions to Measure Fair Value	The fair value of the top-up provision in connection with Sixth Amendment of the Convertible Facility was determined using the Black-Scholes simulation model based on Level 3 inputs on the fair value hierarchy. The following assumptions were used at December 24, 2022: Top-Up Average Stock Price $ 0.02 Weighted-Average Probability 50.00 % Term (in Years) 5 Expected Stock Price Volatility 121.15 %
Schedule of Warrant Issued	The following are the warrants issued related to the equity financing transactions that were accounted for as derivative liabilities: Number of Exercise Expiration March 2021 Private Placement (1) 50,000,000 $0.50 March 27, 2024 50,000,000 _____________________________________
Schedule of Assumptions to Measure Fair Value	The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables: Expected Stock Price Volatility 161.95% Risk-Free Annual Interest Rate 2.35% Expected Life (in Years) 0.25 Share Price $0.02 Exercise Price $0.37

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Dec. 24, 2022
Leases [Abstract]
Schedule of Lease Cost	The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three months ended December 24, 2022 and June 25, 2022: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 267,312 $ 251,221 $ 534,624 $ 534,627 Interest on Lease Liabilities 1,835,068 1,725,752 3,639,574 3,510,293 Operating Lease Cost 2,746,638 4,412,675 6,200,503 8,854,752 Total Lease Expenses $ 4,849,018 $ 6,389,648 $ 10,374,701 $ 12,899,672 Sublease Income (1) $ (1,521,651) $ (1,444,234) $ (3,043,302) $ (1,444,234) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ (1,818) $ — $ 666 $ 959 Operating Cash Flows from Operating Leases $ 474,802 $ 2,298,848 $ 1,501,594 $ 5,777,739 _____________________________________ (1) See “Note 16 – Other Operating Income” for further information. The weighted-average remaining lease term and discount rate related to the Company’s finance and operating lease liabilities as of December 24, 2022 and June 25, 2022, is as follows: December 24, June 25, Weighted-Average Remaining Lease Term (Years) - Finance Leases 46 46 Weighted-Average Remaining Lease Term (Years) - Operating Leases 7 8 Weighted-Average Discount Rate - Finance Leases 24.81 % 24.33 % Weighted-Average Discount Rate - Operating Leases 16.66 % 18.70 %
Future Lease Payments Under Non-cancellable Operating Leases	Future lease payments under non-cancellable operating leases and finance leases as of December 24, 2022 are as follows: Fiscal Year Ending Operating Finance July 1, 2023 (remaining) $ 4,692,026 $ 2,934,524 June 29, 2024 12,931,089 10,961,495 June 28, 2025 9,311,213 7,087,736 June 27, 2026 9,495,658 7,300,368 June 26, 2027 9,466,730 7,519,379 Thereafter 26,267,466 1,061,283,374 Total Lease Payments 72,164,182 1,097,086,876 Less Interest (19,541,732) (1,065,503,555) Lease Liability Recognized $ 52,622,450 $ 31,583,321
Future Lease Payments Under Finance Leases	Future lease payments under non-cancellable operating leases and finance leases as of December 24, 2022 are as follows: Fiscal Year Ending Operating Finance July 1, 2023 (remaining) $ 4,692,026 $ 2,934,524 June 29, 2024 12,931,089 10,961,495 June 28, 2025 9,311,213 7,087,736 June 27, 2026 9,495,658 7,300,368 June 26, 2027 9,466,730 7,519,379 Thereafter 26,267,466 1,061,283,374 Total Lease Payments 72,164,182 1,097,086,876 Less Interest (19,541,732) (1,065,503,555) Lease Liability Recognized $ 52,622,450 $ 31,583,321

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Dec. 24, 2022
Notes Payable [Abstract]
Schedule of Notes Payable	As of December 24, 2022 and June 25, 2022, notes payable consist of the following: December 24, June 25, Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 72,300,000 $ 72,300,000 Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 66,169,035 97,162,001 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10% per annum and require minimum monthly payments of $15,660 and $18,471. 2,057,207 2,057,207 Other 15,691 15,691 Total Notes Payable 140,541,933 171,534,899 Less Unamortized Debt Issuance Costs and Loan Origination Fees (137,478) (158,079) Net Amount 140,404,455 171,376,820 Less Current Portion of Notes Payable (66,294,249) (97,003,922) Notes Payable, Net of Current Portion $ 74,110,206 $ 74,372,898
Schedule of Reconciliation of Notes Payable	A reconciliation of the beginning and ending balances of notes payable for the six months ended December 24, 2022 is as follows: December 24, Balance at Beginning of Period $ 171,376,820 Paid-In-Kind Interest Capitalized 1,257,988 Cash Payments (32,388,433) Accretion of Debt Discount (239,953) Accretion of Debt Discount Included in Discontinued Operations 398,032 Balance at End of Period $ 140,404,454 Less Current Portion of Notes Payable $ (66,294,249) Notes Payable, Net of Current Portion $ 74,110,205

SENIOR SECURED CONVERTIBLE CR_2

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables)	6 Months Ended
	Dec. 24, 2022
Debt Disclosure [Abstract]
Schedule of Senior Secured Convertible Credit Facility	As of December 24, 2022 and June 25, 2022, senior secured convertible credit facility consists of the following: Tranche December 24, June 25, 2022 Senior secured convertible notes dated August 17, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 1A $ 23,944,485 $ 22,880,556 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 1B 103,124,572 98,542,422 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 2 33,534,018 32,043,996 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 3 12,985,058 12,408,091 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. 4 15,273,641 14,594,985 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 24,512,781 23,424,438 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. IA-1 3,428,182 3,275,857 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. IA-2 6,629,552 6,334,980 Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 10,348,746 9,888,919 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 2,292,231 2,190,380 Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on August 17, 2028 and bear interest at LIBOR plus 6.0% per annum. — 12,893,031 12,320,154 Total Drawn on Senior Secured Convertible Credit Facility 248,966,298 237,904,778 Less Unamortized Debt Discount (102,773,249) (105,899,115) Senior Secured Convertible Credit Facility, Net $ 146,193,049 $ 132,005,663 A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the six months ended December 24, 2022 is as follows: Tranche 1 Tranche 2 Tranche 3 Tranche 4 Incremental Advance Incremental Advance 3rd Advance Amendment Restatement Fee Notes 2nd Restatement Fee TOTAL Balance as of June 25, 2022 $ 80,178,586 $ — $ 21,218,356 $ — $ 8,217,079 $ — $ 1,051,827 $ — $ 224,585 $ — $ 433,598 $ — $ 842,981 $ — $ 15,512,409 $ 2,211,711 $ 2,114,531 $ — $ 132,005,663 $ — Paid-In-Kind Interest Capitalized 5,646,079 1,490,022 576,967 678,656 152,325 294,572 572,878 1,088,344 459,827 101,851 11,061,521 Accretion of Debt Discount 1,954,788 514,561 199,249 — — — — 376,148 73,578 7,541 3,125,865 Balance as of December 24, 2022 $ 87,779,453 $ 23,222,939 $ 8,993,295 $ 1,730,483 $ 376,910 $ 728,170 $ 1,415,859 $ 16,976,901 $ 2,745,116 $ — $ 2,223,923 $ 146,193,049

SHAREHOLDERS_ EQUITY (Tables)

SHAREHOLDERS’ EQUITY (Tables)	6 Months Ended
	Dec. 24, 2022
Equity [Abstract]
Schedule of Shares Issued and Outstanding	A reconciliation of the beginning and ending issued and outstanding shares is as follows: Subordinate MM CAN USA MM Enterprises USA Balance as of June 25, 2022 1,301,423,950 65,066,106 725,016 Redemption of MedMen Corp Redeemable Shares 259,814 (259,814) — Balance as of September 24, 2022 1,301,683,764 64,806,292 725,016 Redemption of MedMen Corp Redeemable Shares 445,320 (445,320) — Balance as of December 24, 2022 1,302,129,084 64,360,972 725,016
Schedule of VIE	As of and for the six months ended December 24, 2022, the balances and activities attributable to the VIEs consist of the following: Venice Caregivers LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,471,651 $ — $ 27,171,414 $ 28,643,065 Non-Current Assets 8,482,483 3,011,882 4,874,353 16,368,718 Total Assets $ 9,954,134 $ 3,011,882 $ 32,045,767 $ 45,011,783 Current Liabilities $ 10,984,598 $ 16,687,993 $ 10,031,350 $ 37,703,941 Non-Current Liabilities 6,957,566 1,922,553 1,342,632 10,222,751 Total Liabilities $ 17,942,164 $ 18,610,546 $ 11,373,982 $ 47,926,692 Non-Controlling Interest $ (7,988,030) $ (15,598,664) $ 20,671,785 $ (2,914,909) Revenues $ 3,766,847 $ — $ 6,562,185 $ 10,329,032 Net (Loss) Income Attributable to Non-Controlling Interest $ (944,589) $ (1,622,510) $ 1,917,227 $ (649,872) As of and for the fiscal year ended June 25, 2022, the balances of the VIEs consists of the following: Venice Caregivers LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,735,304 $ 1,067,636 $ 23,557,168 $ 26,360,108 Non-Current Assets 10,073,880 3,379,412 4,973,459 18,426,751 Total Assets $ 11,809,184 $ — $ 4,447,048 $ — $ 28,530,627 $ 44,786,859 Current Liabilities $ 9,238,460 $ 16,238,249 $ 8,433,436 $ 33,910,145 Non-Current Liabilities 9,614,164 2,184,953 1,342,633 13,141,750 Total Liabilities $ 18,852,624 $ — $ 18,423,202 $ — $ 9,776,069 $ 47,051,895 Non-Controlling Interest $ (7,043,440) $ — $ (13,976,154) $ — $ 18,754,558 $ — $ (2,265,036) Revenues $ 4,815,688 $ — $ 8,816,113 $ 13,631,801 Net (Loss) Income Attributable to Non-Controlling Interest $ (607,858) $ (2,206,450) $ 3,911,125 $ 1,096,817
Schedule of Other Non-controlling Interest	The net change in the consolidated VIEs and other non-controlling interest are as follows for the six months ended December 24, 2022: Venice Caregivers LAX Fund II Group, LLC Natures Cure, Inc. Other Non- Controlling TOTAL Balance as of June 25, 2022 $ (7,043,440) $ (13,976,154) $ 18,754,558 $ (471,717,698) $ (473,982,734) Net (Loss) Income $ (944,589) $ (1,622,510) $ 1,917,227 $ (597,289) $ (1,247,161) Balance as of December 24, 2022 $ (7,988,029) $ (15,598,664) $ 20,671,785 $ (472,314,987) $ (475,229,895)

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Dec. 24, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense	A summary of share-based compensation expense for the three and six months ended December 24, 2022 and December 25, 2021 is as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Stock Options $ 1,912,792 $ 97,746 $ 2,625,581 $ 1,314,193 Stock Grants for Compensation — 207,494 — 540,827 Restricted Stock Grants 200,884 402,866 351,780 1,957,163 Total Share-Based Compensation $ 2,113,676 $ 708,106 $ 2,977,361 $ 3,812,183
Schedule of Stock Options	A reconciliation of the beginning and ending balance of stock options outstanding is as follows: Number of Weighted-Average Outstanding at June 25, 2022 8,649,673 $ 1.35 Granted 92,382,965 0.05 Forfeited (312,032) 3.60 Outstanding at December 24, 2022 100,720,606 $ 0.15 Stock Options Exercisable as of December 24, 2022 8,037,095
Schedule of LTIP Units and LLC Redeemable Units	A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows: LTIP Units LLC Weighted Issued and Balance as of June 25, 2022 and December 24, 2022 19,323,878 725,016 $ 0.52
Schedule of Restricted Stock Grants	A reconciliation of the beginning and ending balance of restricted stock units outstanding is as follows: Issued and Vested Weighted-Average Balance as of June 25, 2022 10,998,483 4,030,460 $ 0.20 Granted — — — Vested — 490,661 0.21 Forfeited (1) (1,813,408) — (0.22) Non-vested at December 24, 2022 9,185,075 4,521,121 $ 0.30 _____________________________________ (1) Restricted stock units represent units forfeited upon resignation of certain employees prior to their vesting.
Schedule of Warrants	A reconciliation of the beginning and ending balance of warrants outstanding is as follows: Number of Warrants Outstanding Subordinate MM CAN USA TOTAL Weighted-Average Balance as of June 25, 2022 352,704,355 97,430,456 450,134,811 $ 0.25 Expired (6,023,696) — (6,023,696) $ 2.03 Balance as of December 24, 2022 346,680,659 97,430,456 444,111,115 $ 0.22

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	Dec. 24, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Share	The following is a reconciliation for the calculation of basic and diluted loss per share for the three and six months ended December 24, 2022 and December 25, 2021 is as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (15,086) $ (8,217) $ (39,427) $ (54,381) Net Income (Loss) from Discontinued Operations (2,256) (12,141) 26,132 (26,587) Total Loss $ (17,342) $ (20,358) $ (13,294) $ (80,968) Denominator: Weighted-Average Shares Outstanding - Basic 1,301,874,615 1,198,515,279 1,301,767,158 1,070,605,666 Dilutive effect of LTIP and LLC Redeemable Units issued for compensation 19,323,878 19,323,878 19,323,878 19,323,878 Dilutive effect of restricted stock granted under the Equity Plan 9,185,075 25,673,720 9,185,075 25,673,720 Dilutive effect of warrants and top-up warrants 194,720,261 138,498,284 258,878,685 175,668,177 Dilutive effect of convertible debentures 3,255,897,270 1,007,089,116 3,255,897,270 1,007,089,116 Weighted-Average Shares Outstanding - Diluted (1) 4,781,001,100 2,389,100,278 4,845,052,067 2,298,360,557

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	6 Months Ended
	Dec. 24, 2022
General And Administrative Expenses
Schedule of General and Administrative Expenses	During the three and six months ended December 24, 2022 and December 25, 2021, general and administrative expenses consisted of the following: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Salaries and Benefits $ 6,536,411 $ 9,991,545 $ 13,468,859 $ 19,903,033 Professional Fees 2,137,010 7,815,185 3,509,420 15,245,844 Rent 3,021,217 4,712,476 6,649,162 9,467,359 Licenses, Fees and Taxes 1,823,436 1,293,194 3,866,945 3,830,982 Share-Based Compensation 2,113,676 722,802 2,977,361 2,370,111 Deal Costs — 1,174,357 429,272 2,811,944 Other General and Administrative 2,709,471 5,583,195 5,551,538 10,312,715 Total General and Administrative Expenses $ 18,341,221 $ 31,292,754 $ 36,452,557 $ 63,941,988

OTHER OPERATING (INCOME) EXPE_2

OTHER OPERATING (INCOME) EXPENSE (Tables)	6 Months Ended
	Dec. 24, 2022
Other Operating Income Expense
Schedule of Other Operating Expenses	During the three and six months ended December 24, 2022 and December 25, 2021 , other operating (income) expense consisted of the following: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Other Operating (Income) Expense: Loss (Gain) on Disposals of Assets $ 1,153,225 $ (141,662) $ 1,358,820 $ (126,516) Restructuring and Reorganization Expense — 385,652 423,793 2,764,327 Gain on Settlement of Accounts Payable 215,659 — 141,022 (177,990) (Gain) Loss on Lease Terminations (1,877,298) 173,765 (3,464,947) 173,765 (Gain) Loss on Disposal of Assets Held for Sale (112,225) — 532,598 — Legal Settlements (3,491,431) — (3,491,431) — Other Income (1,522,280) 213,216 (3,043,918) 196,413 Total Other Operating (Income) Expense $ (5,634,350) $ 630,971 $ (7,544,063) $ 2,829,999

PROVISION FOR INCOME TAXES AN_2

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables)	6 Months Ended
	Dec. 24, 2022
Income Tax Disclosure [Abstract]
Schedule of Income Tax Expense and Effective Tax Rates	The following table summarizes the Company’s income tax expense and effective tax rates for the three and six months ended December 24, 2022 and December 25, 2021 Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Loss from Continuing Operations Before Provision for Income Taxes $ (14,025,468) $ (16,355,274) $ (32,673,967) $ (42,826,906) Provision for Income Tax Expense (1,060,808) 8,137,898 (6,752,886) (11,554,010) Effective Tax Rate 8 % -50 % 21 % 27 %

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
	Dec. 24, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Revenue by state for the periods presented are as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, California $ 19,575,393 $ 23,368,439 $ 39,504,378 $ 47,994,994 Nevada 2,812,902 3,855,371 5,810,371 7,934,522 Illinois 3,082,089 4,104,970 6,624,159 8,433,572 Arizona 3,343,592 4,173,609 6,138,238 7,875,206 Massachusetts 734,394 14,772 1,515,277 14,771 Revenue from Continuing Operations 29,548,370 35,517,161 59,592,423 72,253,065 Revenue from Discontinued Operations 2,282,288 8,065,341 5,911,927 15,405,440 Total Revenue $ 31,830,658 $ 43,582,502 $ 65,504,350 $ 87,658,505

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Dec. 24, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Net Operating Loss of Discontinued Operation	The operating results of the discontinued operations are summarized as follows: Three Months Ended Six Months Ended December 24, December 25, December 24, December 25, Revenue $ 2,282,288 $ 8,065,341 $ 5,911,927 $ 15,405,440 Cost of Goods Sold 439,466 5,672,043 2,630,135 10,899,596 Gross Profit 1,842,822 2,393,298 3,281,792 4,505,844 Expenses: General and Administrative 2,134,342 6,329,144 6,853,135 11,946,739 Sales and Marketing 15,015 127,844 58,326 231,647 Depreciation and Amortization 21,107 1,189,331 894,002 2,411,090 Impairment Expense — — (78,433) — Gain on Disposal of Assets and Other Income — — (36,305,166) (597,591) Total (Income) Expenses $ 2,170,464 $ 7,646,319 $ (28,578,136) $ 13,991,885 Income (Loss) from Discontinued Operations (327,642) (5,253,021) 31,859,928 (9,486,041) Other Expense: Interest Expense 1,783,685 4,755,126 5,545,446 9,371,955 Accretion of Debt Discount and Loan Origination Fees — 3,446,949 398,032 6,987,857 Total Other Expense 1,783,685 8,202,075 5,943,478 16,359,812 Income (Loss) from Discontinued Operations Before Provision for Income Taxes (2,111,327) (13,455,096) 25,916,450 (25,845,853) Provision for Income Tax Benefit (Expense) (144,651) 1,314,496 216,039 (741,238) Net Income (Loss) from Discontinued Operations $ (2,255,978) $ (12,140,600) $ 26,132,489 $ (26,587,091)
Schedule of Assets Included in Discontinued Operation	The carrying amounts of assets and liabilities in the disposal group are summarized as follows: December 24, June 25, Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents $ 540,828 $ 1,124,076 Restricted Cash 5,280 5,280 Accounts Receivable and Prepaid Expenses 22,019 334,621 Inventory 4,483,051 6,866,833 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 9,569,610 41,273,597 Operating Lease Right-of-Use Assets 19,111,359 31,543,058 Intangible Assets, Net 10,582,559 40,799,146 Other Assets 458,383 1,181,795 TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE 44,773,089 123,128,406 Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities $ 979,864 $ 6,295,745 Income Taxes Payable 389,677 1,671,380 Other Current Liabilities (5,641) 89,069 Current Portion of Operating Lease Liabilities 2,812,765 4,209,512 Current Portion of Finance Lease Liabilities — 174,000 TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 18,398,345 56,410,071 Deferred Tax Liabilities 5,977,580 6,097,597 Notes Payable — 11,100,000 TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 28,552,590 $ 86,047,374

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details)	Dec. 24, 2022 store
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of stores	23

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 25, 2022	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Accounting Policies [Abstract]
Cash and Cash Equivalents	$ 10,795,999	$ 15,605,362		$ 15,605,362
Net working capital deficit		(137,433,003)		(137,433,003)
Net Loss from Continuing Operations		$ (15,086,276)	$ (8,217,376)	$ (39,426,853)	$ (54,380,916)
Reclassifications impacted leasehold improvements and furniture and fixtures	940,000
Reclassifications impacted customer relationships and accumulated amortization	1,440,000
Reclassifications impacted accumulated amortization	964,000
Reclassifications impacted non-controlling interest and accumulated deficit	3,662,000
Reclassifications impacted short-term and long-term operating lease liabilities	$ 6,825,000

INVENTORY - Schedule of Invento

INVENTORY - Schedule of Inventories (Details) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Inventory Disclosure [Abstract]
Raw Materials	$ 736,389	$ 521,777
Work-in-Process	956,705	671,541
Finished Goods	11,982,228	8,817,413
Total Inventory	$ 13,675,322	$ 10,010,731

INVENTORY - Narrative (Details)

INVENTORY - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Inventory Disclosure [Abstract]
Other asset impairment charges	$ 0	$ 0	$ 0	$ 900

ASSETS HELD FOR SALE - Schedule

ASSETS HELD FOR SALE - Schedule of Asset Held for Sale (Details)	6 Months Ended
	Dec. 24, 2022 USD ($)
Assets Held-for-sale [Roll Forward]
Balance at Beginning of Period	$ 123,158,751
Balance at End of Period	43,611,513
Discontinued Operations & Other Assets
Assets Held-for-sale [Roll Forward]
Balance at Beginning of Period	123,158,751
Ongoing Activities	(12,547,238)
Proceeds from Sale	(67,000,000)
Balance at End of Period	$ 43,611,513

PROPERTY AND EQUIPMENT - Schedu

PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Property, Plant and Equipment [Abstract]
Land and Buildings	$ 29,933,999	$ 29,933,999
Capital Leases	5,318,516	5,315,625
Furniture and Fixtures	8,651,132	8,776,994
Leasehold Improvements	33,625,888	33,069,524
Equipment and Software	15,972,636	16,897,649
Construction in Progress	4,169,772	6,828,923
Total Property and Equipment	97,671,943	100,822,714
Less Accumulated Depreciation	(40,026,614)	(36,714,922)
Property and Equipment, Net	$ 57,645,329	$ 64,107,792

PROPERTY AND EQUIPMENT - Narrat

PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,499,585	$ 6,864,790	$ 7,471,055	$ 13,121,707
Depreciation recognized for capital leases	$ 267,312	267,312	$ 534,624	534,624
Borrowing costs		$ 375,241		$ 375,241
Average capitalization rate		11.95%		11.95%

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 77,093,119	$ 77,093,119
Less Accumulated Amortization	(44,439,985)	(41,347,005)
Intangible Assets, Net	32,653,134	35,746,114
Capitalized Software
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	7,413,470	7,413,470
Less Accumulated Amortization	(4,824,287)	(4,413,974)
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	16,409,600	16,409,600
Less Accumulated Amortization	(15,378,567)	(15,870,284)
Intellectual Property
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	12,455,287	4,016,597
Less Accumulated Amortization	(6,152,763)	(4,185,835)
Dispensary Licenses
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	40,814,762	49,253,452
Less Accumulated Amortization	$ (18,084,368)	$ (16,876,912)

INTANGIBLE ASSETS - Narrative (

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Depreciation, depletion and amortization, nonproduction	$ 1,410,858	$ 3,206,091	$ 3,123,979	$ 6,431,928

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Extinguishment of Debt [Line Items]
Total Accounts Payable and Accrued Liabilities	$ 42,926,092	$ 38,905,818
Accounts Payable and Accrued Liabilities
Extinguishment of Debt [Line Items]
Accounts Payable	19,663,409	14,627,746
Accrued Liabilities	9,862,983	9,464,567
Accrued Inventory	6,397,508	5,868,831
Accrued Payroll	1,405,253	1,682,517
Local & State Taxes Payable	5,030,310	6,695,532
Deferred Gain on Sale of Assets	566,627	566,627
Total Accounts Payable and Accrued Liabilities	$ 42,926,090	$ 38,905,820

DERIVATIVE LIABILITIES - Schedu

DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities (Details) - USD ($)	6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021
Derivative Instruments [Roll Forward]
Change in Fair Value of Derivative Liabilities	$ (3,106,786)	$ (16,211,785)
Derivative Liabilities One
Derivative Instruments [Roll Forward]
Balance at Beginning of Period	6,749,563
Change in Fair Value of Derivative Liabilities	(3,106,786)
Balance at End of Period	$ 3,642,777

DERIVATIVE LIABILITIES - Sche_2

DERIVATIVE LIABILITIES - Schedule of Assumptions to Measure Fair Value (Details)	6 Months Ended
	Dec. 24, 2022 $ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Average Stock Price (in dollars per share)	$ 0.02
Term (in Years)	3 months
Expected Stock Price Volatility	161.95%
Top Up Provision
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Average Stock Price (in dollars per share)	$ 0.02
Weighted-Average Probability	50%
Term (in Years)	5 years
Expected Stock Price Volatility	121.15%

DERIVATIVE LIABILITIES - Sche_3

DERIVATIVE LIABILITIES - Schedule of Warrant Issued (Details)	Dec. 24, 2022 $ / shares shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of Warrants | shares	50,000,000
Exercise Price (in dollars per share) | $ / shares	$ 0.50

DERIVATIVE LIABILITIES - Sche_4

DERIVATIVE LIABILITIES - Schedule of Assumptions to Measure Fair Value (Details)	6 Months Ended
	Dec. 24, 2022 $ / shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Expected Stock Price Volatility	161.95%
Risk-Free Annual Interest Rate	2.35%
Expected Life (in Years)	3 months
Share Price (in dollars per share)	$ 0.02
Exercise Price (in dollars per share)	$ 0.37

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Cost (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021	Jun. 25, 2022
Finance Lease Cost:
Amortization of Finance Lease Right-of-Use Assets	$ 267,312	$ 251,221	$ 534,624	$ 534,627
Interest on Lease Liabilities	1,835,068	1,725,752	3,639,574	3,510,293
Operating Lease Cost	2,746,638	4,412,675	6,200,503	8,854,752
Total Lease Expenses	4,849,018	6,389,648	10,374,701	12,899,672
Sublease Income	(1,521,651)	(1,444,234)	(3,043,302)	(1,444,234)
Cash Paid for Amounts Included in the Measurement of Lease Liabilities:
Financing Cash Flows from Finance Leases	(1,818)	0	666	959
Operating Cash Flows from Operating Leases	$ 474,802	$ 2,298,848	$ 1,501,594	$ 5,777,739
Weighted-Average Remaining Lease Term (Years) - Finance Leases	46 years		46 years		46 years
Weighted-Average Remaining Lease Term (Years) - Operating Leases	7 years		7 years		8 years
Weighted-Average Discount Rate - Finance Leases	24.81%		24.81%		24.33%
Weighted-Average Discount Rate - Operating Leases	16.66%		16.66%		18.70%

LEASES - Schedule of Future Lea

LEASES - Schedule of Future Leases Payments (Details)	6 Months Ended
	Dec. 24, 2022 USD ($)
Operating Leases
July 1, 2023 (remaining)	$ 4,692,026
June 29, 2024	12,931,089
June 28, 2025	9,311,213
June 27, 2026	9,495,658
June 26, 2027	9,466,730
Thereafter	26,267,466
Total Lease Payments	72,164,182
Less Interest	(19,541,732)
Lease Liability Recognized	52,622,450
Finance Leases
July 1, 2023 (remaining)	2,934,524
June 29, 2024	10,961,495
June 28, 2025	7,087,736
June 27, 2026	7,300,368
June 26, 2027	7,519,379
Thereafter	1,061,283,374
Total Lease Payments	1,097,086,876
Less Interest	(1,065,503,555)
Lease Liability Recognized	31,583,321
Purchase option	$ 1
California Cultivation Facilities
Lessee, Lease, Description [Line Items]
Management Agreement fee, rate	100%
Nevada Cultivation Facilities
Lessee, Lease, Description [Line Items]
Management Agreement fee, rate	30%

NOTES PAYABLE - Schedule of Not

NOTES PAYABLE - Schedule of Notes Payable (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 24, 2022	Jun. 25, 2022
Short-Term Debt [Line Items]
Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.	$ 4,294,333	$ 4,061,273
Total Notes Payable	74,110,205	74,372,898
Less Current Portion of Notes Payable	(66,294,249)	(97,003,922)
Convertible Notes Payable
Short-Term Debt [Line Items]
Other	15,691	15,691
Total Notes Payable	140,541,933	171,534,899
Less Unamortized Debt Issuance Costs and Loan Origination Fees	(137,478)	(158,079)
Net Amount	140,404,455	171,376,820
Less Current Portion of Notes Payable	(66,294,249)	(97,003,922)
Notes Payable, Net of Current Portion	74,110,206	74,372,898
Convertible Notes Payable | Financing Liability
Short-Term Debt [Line Items]
Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum.	$ 72,300,000	$ 72,300,000
Interest rate	0.70%	17%
Convertible Notes Payable | Non-revolving Senior Secured Term Notes
Short-Term Debt [Line Items]
Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on August 1, 2022 and July 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum.	$ 66,169,035	$ 97,162,001
Interest rate	15.50%	18%
Convertible Notes Payable | Promissory Notes
Short-Term Debt [Line Items]
Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10% per annum and require minimum monthly payments of $15,660 and $18,471.	$ 2,057,207	$ 2,057,207
Interest rate	10%	10%
Minimum monthly payment	$ 15,660	$ 18,471

NOTES PAYABLE - Schedule of Rec

NOTES PAYABLE - Schedule of Reconciliation of Notes Payable (Details) - Notes Payable	6 Months Ended
	Dec. 24, 2022 USD ($)
Short-Term Debt [Roll Forward]
Balance at beginning of period	$ 171,376,820
Paid-In-Kind Interest Capitalized	1,257,988
Cash Payments	(32,388,433)
Accretion of Debt Discount	(239,953)
Accretion of Debt Discount Included in Discontinued Operations	398,032
Balance at End of period	140,404,454
Less Current portion of notes payables	(66,294,249)
Notes Issued	$ 74,110,205

NOTES PAYABLE - Narrative (Deta

NOTES PAYABLE - Narrative (Details) - USD ($) $ in Millions	1 Months Ended		6 Months Ended	12 Months Ended
	Dec. 24, 2022	Feb. 28, 2022	Dec. 24, 2022	Dec. 31, 2023
Short-Term Debt [Line Items]
Mandatory prepayment		$ 37.5
Principal repayment			$ 31.6
Default interest rate	5%
Forecast
Short-Term Debt [Line Items]
Repayments of debt				$ 8.5

SENIOR SECURED CONVERTIBLE CR_3

SENIOR SECURED CONVERTIBLE CREDIT FACILITY - Schedule of Senior Secured Convertible Credit Facility (Details) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 248,966,298	$ 237,904,778
Less Unamortized Debt Discount	(102,773,249)	(105,899,115)
Senior Secured Convertible Credit Facility, Net	146,193,049	132,005,663
Secured Convertible Note
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 23,944,485	$ 22,880,556
Interest rate	6%	6%
Secured Convertible Note 1
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 103,124,572	$ 98,542,422
Interest rate	6%	6%
Secured Convertible Note 2
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 33,534,018	$ 32,043,996
Interest rate	6%	6%
Secured Convertible Note 3
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 12,985,058	$ 12,408,091
Interest rate	6%	6%
Secured Convertible Note 4
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 15,273,641	$ 14,594,985
Interest rate	6%	6%
Secured Convertible Note 5
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 24,512,781	$ 23,424,438
Interest rate	6%	6%
Secured Convertible Note 6
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 3,428,182	$ 3,275,857
Interest rate	6%	6%
Secured Convertible Note 7
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 6,629,552	$ 6,334,980
Interest rate	6%	6%
Secured Convertible Note 8
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 10,348,746	$ 9,888,919
Interest rate	6%	6%
Secured Convertible Note 9
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 2,292,231	$ 2,190,380
Interest rate	6%	6%
Secured Convertible Note 10
Schedule of Capitalization, Long-Term Debt [Line Items]
Total Drawn on Senior Secured Convertible Credit Facility	$ 12,893,031	$ 12,320,154
Interest rate	6%	6%

SENIOR SECURED CONVERTIBLE CR_4

SENIOR SECURED CONVERTIBLE CREDIT FACILITY - Narrative (Details)	6 Months Ended
	Dec. 24, 2022 USD ($)
Senior Secured Convertible Total
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	$ 132,005,663
Paid-In-Kind Interest Capitalized	11,061,521
Accretion of Debt Discount	3,125,865
Balance at end of period	146,193,049
Tranche 1
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	80,178,586
Paid-In-Kind Interest Capitalized	5,646,079
Accretion of Debt Discount	1,954,788
Balance at end of period	87,779,453
Tranche 2
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	21,218,356
Paid-In-Kind Interest Capitalized	1,490,022
Accretion of Debt Discount	514,561
Balance at end of period	23,222,939
Tranche 3
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	8,217,079
Paid-In-Kind Interest Capitalized	576,967
Accretion of Debt Discount	199,249
Balance at end of period	8,993,295
Tranche 4
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	1,051,827
Paid-In-Kind Interest Capitalized	678,656
Accretion of Debt Discount	0
Balance at end of period	1,730,483
Incremental Advance - 1
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	224,585
Paid-In-Kind Interest Capitalized	152,325
Accretion of Debt Discount	0
Balance at end of period	376,910
Incremental Advance - 2
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	433,598
Paid-In-Kind Interest Capitalized	294,572
Accretion of Debt Discount	0
Balance at end of period	728,170
3rd Advance
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	842,981
Paid-In-Kind Interest Capitalized	572,878
Accretion of Debt Discount	0
Balance at end of period	1,415,859
Amendment Fee Notes
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	15,512,409
Paid-In-Kind Interest Capitalized	1,088,344
Accretion of Debt Discount	376,148
Balance at end of period	16,976,901
Restatement Fee Notes
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	2,211,711
Paid-In-Kind Interest Capitalized	459,827
Accretion of Debt Discount	73,578
Balance at end of period	2,745,116
2nd Restatement Fee Notes
Convertible Debt, Reconciliation [Roll Forward]
Balance at beginning of period	2,114,531
Paid-In-Kind Interest Capitalized	101,851
Accretion of Debt Discount	7,541
Balance at end of period	$ 2,223,923

SHAREHOLDERS' EQUITY - Schedule

SHAREHOLDERS' EQUITY - Schedule of Shares Issued and Outstanding (Details) - shares	3 Months Ended
	Dec. 24, 2022	Sep. 24, 2022
MM CAN USA Class B Redeemable Units
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	64,806,292	65,066,106
Redemption of MedMen Corp Redeemable (in shares)	(445,320)	(259,814)
Ending balance (in shares)	64,360,972	64,806,292
MM Enterprises USA Common Units
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	725,016	725,016
Redemption of MedMen Corp Redeemable (in shares)	0	0
Ending balance (in shares)	725,016	725,016
Subordinate Voting Shares
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	1,301,683,764	1,301,423,950
Redemption of MedMen Corp Redeemable (in shares)	445,320	259,814
Ending balance (in shares)	1,302,129,084	1,301,683,764

SHAREHOLDERS_ EQUITY - Narrativ

SHAREHOLDERS’ EQUITY - Narrative (Details)	Dec. 24, 2022	Jun. 25, 2022
MM CAN USA
Class of Stock [Line Items]
Ownership percentage	4.71%	4.76%
MM Enterprises USA
Class of Stock [Line Items]
Ownership percentage		0.05%

SHAREHOLDERS' EQUITY - Schedu_2

SHAREHOLDERS' EQUITY - Schedule of VIE (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021	Jun. 25, 2022
Class of Stock [Line Items]
Current Assets	$ 100,211,425		$ 100,211,425		$ 161,496,240
TOTAL ASSETS	238,475,011		238,475,011		323,223,684
Current Liabilities	237,644,428		237,644,428		319,591,380
TOTAL LIABILITIES	567,267,179		567,267,179		641,736,420
Revenue	29,554,100	$ 35,517,161	59,598,153	$ 72,253,065
Variable Interest Entity (VIE)
Class of Stock [Line Items]
Current Assets	28,643,065		28,643,065		26,360,108
Non-Current Assets	16,368,718		16,368,718		18,426,751
TOTAL ASSETS	45,011,783		45,011,783		44,786,859
Current Liabilities	37,703,941		37,703,941		33,910,145
Non-Current Liabilities	10,222,751		10,222,751		13,141,750
TOTAL LIABILITIES	47,926,692		47,926,692		47,051,895
Non-Controlling Interest	(2,914,909)		(2,914,909)		(2,265,036)
Revenue			10,329,032		13,631,801
Net (Loss) Income Attributable to Non-Controlling Interest			(649,872)		1,096,817
Venice Caregivers Foundation, Inc. | Variable Interest Entity (VIE)
Class of Stock [Line Items]
Current Assets	1,471,651		1,471,651		1,735,304
Non-Current Assets	8,482,483		8,482,483		10,073,880
TOTAL ASSETS	9,954,134		9,954,134		11,809,184
Current Liabilities	10,984,598		10,984,598		9,238,460
Non-Current Liabilities	6,957,566		6,957,566		9,614,164
TOTAL LIABILITIES	17,942,164		17,942,164		18,852,624
Non-Controlling Interest	(7,988,030)		(7,988,030)		(7,043,440)
Revenue			3,766,847		4,815,688
Net (Loss) Income Attributable to Non-Controlling Interest			(944,589)		(607,858)
LAX Fund II Group, LLC | Variable Interest Entity (VIE)
Class of Stock [Line Items]
Current Assets	0		0		1,067,636
Non-Current Assets	3,011,882		3,011,882		3,379,412
TOTAL ASSETS	3,011,882		3,011,882		4,447,048
Current Liabilities	16,687,993		16,687,993		16,238,249
Non-Current Liabilities	1,922,553		1,922,553		2,184,953
TOTAL LIABILITIES	18,610,546		18,610,546		18,423,202
Non-Controlling Interest	(15,598,664)		(15,598,664)		(13,976,154)
Revenue			0		0
Net (Loss) Income Attributable to Non-Controlling Interest			(1,622,510)		(2,206,450)
Natures Cure, Inc. | Variable Interest Entity (VIE)
Class of Stock [Line Items]
Current Assets	27,171,414		27,171,414		23,557,168
Non-Current Assets	4,874,353		4,874,353		4,973,459
TOTAL ASSETS	32,045,767		32,045,767		28,530,627
Current Liabilities	10,031,350		10,031,350		8,433,436
Non-Current Liabilities	1,342,632		1,342,632		1,342,633
TOTAL LIABILITIES	11,373,982		11,373,982		9,776,069
Non-Controlling Interest	$ 20,671,785		20,671,785		18,754,558
Revenue			6,562,185		8,816,113
Net (Loss) Income Attributable to Non-Controlling Interest			$ 1,917,227		$ 3,911,125

SHAREHOLDERS' EQUITY - Schedu_3

SHAREHOLDERS' EQUITY - Schedule of Other Non-controlling Interest (Details) - USD ($)	3 Months Ended				6 Months Ended
	Dec. 24, 2022	Sep. 24, 2022	Dec. 25, 2021	Sep. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net (Loss) Income	$ (17,342,254)	$ 4,047,901	$ (20,357,976)	$ (60,610,031)	$ (13,294,364)	$ (80,968,007)
Non Controlling Interests [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance		(473,982,734)			(473,982,734)
Net (Loss) Income					(1,247,161)
Ending balance	(475,229,895)				(475,229,895)
Venice Caregivers Foundation, Inc. | Non Controlling Interests [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance		(7,043,440)			(7,043,440)
Net (Loss) Income					(944,589)
Ending balance	(7,988,029)				(7,988,029)
LAX Fund II Group, LLC | Non Controlling Interests [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance		(13,976,154)			(13,976,154)
Net (Loss) Income					(1,622,510)
Ending balance	(15,598,664)				(15,598,664)
Natures Cure, Inc. | Non Controlling Interests [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance		18,754,558			18,754,558
Net (Loss) Income					1,917,227
Ending balance	20,671,785				20,671,785
Other Non- Controlling Interests | Non Controlling Interests [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance		$ (471,717,698)			(471,717,698)
Net (Loss) Income					(597,289)
Ending balance	$ (472,314,987)				$ (472,314,987)

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details)	6 Months Ended
	Dec. 24, 2022
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting period	5 years
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting period	10 years

SHARE-BASED COMPENSATION - Sche

SHARE-BASED COMPENSATION - Schedule of Share-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Share-Based Compensation	$ 2,113,676	$ 708,106	$ 2,977,361	$ 3,812,183
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Share-Based Compensation	1,912,792	97,746	2,625,581	1,314,193
Stock Grants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Share-Based Compensation	0	207,494	0	540,827
Restricted Stock Grants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Share-Based Compensation	$ 200,884	$ 402,866	$ 351,780	$ 1,957,163

SHARE-BASED COMPENSATION - Sc_2

SHARE-BASED COMPENSATION - Schedule of Stock Options (Details)	6 Months Ended
	Dec. 24, 2022 $ / shares shares
Number of Stock Options
Beginning balance (in shares) | shares	8,649,673
Granted (in shares) | shares	92,382,965
Forfeited and Expired (in shares) | shares	(312,032)
Ending balance (in shares) | shares	100,720,606
Stock Options Exercisable (in shares) | shares	8,037,095
Weighted-Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 1.35
Granted (in dollars per share) | $ / shares	0.05
Forfeited and Expired (in dollars per share) | $ / shares	3.60
Ending balance (in dollars per share) | $ / shares	0.15
Stock Options Exercisable (in dollars per share) | $ / shares

SHARE-BASED COMPENSATION - Sc_3

SHARE-BASED COMPENSATION - Schedule of LTIP Units and LLC Redeemable Units (Details)	Dec. 24, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
LTIP Issued And Outstanding (in shares)	19,323,878
LLC Redeemable Units (in shares)	725,016
Weighted Average grant date fair Value (in dollars per share) | $ / shares	$ 0.52

SHARE-BASED COMPENSATION - Sc_4

SHARE-BASED COMPENSATION - Schedule of Restricted Stock Grants (Details) - $ / shares	6 Months Ended
	Dec. 24, 2022	Jun. 25, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Issued And Outstanding, Beginning Balance (in shares)		10,998,483
Vested, Beginning Balance (in shares)		4,030,460
Weighted average fair value at beginning (in dollars per share)	$ 0.20
Vested, Vesting of Restricted Stock (in shares)	490,661
Weighted Average Fair Value, Vesting of Restricted Stock (in dollars per share)	$ 0.21
Issued And Outstanding, Forfeiture of Restricted Stock (in shares)	(1,813,408)
Weighted Average Fair Value, Forfeiture of Restricted Stock (in dollars per share)	$ (0.22)
Issued And Outstanding, Ending Balance (in shares)	9,185,075
Vested, Ending Balance (in shares)	4,521,121
Weighted average fair value at ending (in dollars per share)	$ 0.30

SHARE-BASED COMPENSATION - Sc_5

SHARE-BASED COMPENSATION - Schedule of Warrants (Details) - Warrant - $ / shares	6 Months Ended
	Dec. 24, 2022	Jun. 25, 2022
Warrants Outstanding [Roll Forward]
Beginning Balance		450,134,811
Weighted Average Exercise Price, Beginning balance		$ 0.25
Expired	(6,023,696)
Weighted Average Exercise Price, Expired	$ 2.03
Ending Balance	444,111,115
Weighted Average Exercise Price, Ending	$ 0.22
Subordinate Voting Shares
Warrants Outstanding [Roll Forward]
Beginning Balance		352,704,355
Expired	(6,023,696)
Ending Balance	346,680,659
MM CAN USA Class B Redeemable Units
Warrants Outstanding [Roll Forward]
Beginning Balance		97,430,456
Expired	0
Ending Balance	97,430,456

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($)	3 Months Ended				6 Months Ended
	Dec. 24, 2022	Sep. 24, 2022	Dec. 25, 2021	Sep. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Earnings Per Share [Abstract]
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.	$ (15,086,000)		$ (8,217,000)		$ (39,427,000)	$ (54,381,000)
Net Income (Loss) from Discontinued Operations	(2,256,000)		(12,141,000)		26,132,000	(26,587,000)
Net (Loss) Income	$ (17,342,254)	$ 4,047,901	$ (20,357,976)	$ (60,610,031)	$ (13,294,364)	$ (80,968,007)
Weighted-Average Shares Outstanding - Basic (in shares)	1,301,874,615		1,198,515,279		1,301,767,158	1,070,605,666
Dilutive effect of LTIP and LLC Redeemable Units issued for compensation (in shares)	19,323,878		19,323,878		19,323,878	19,323,878
Dilutive effect of restricted stock granted under the Equity Plan (in shares)	9,185,075		25,673,720		9,185,075	25,673,720
Dilutive effect of warrants and top-up warrants (in shares)	194,720,261		138,498,284		258,878,685	175,668,177
Dilutive effect of convertible debentures (in shares)	3,255,897,270		1,007,089,116		3,255,897,270	1,007,089,116
Weighted-Average Shares Outstanding - Diluted (in shares)	4,781,001,100		2,389,100,278		4,845,052,067	2,298,360,557

GENERAL AND ADMINISTRATIVE EX_3

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
General And Administrative Expenses
Salaries and Benefits	$ 6,536,411	$ 9,991,545	$ 13,468,859	$ 19,903,033
Professional Fees	2,137,010	7,815,185	3,509,420	15,245,844
Total Lease Expenses	3,021,217	4,712,476	6,649,162	9,467,359
Licenses, Fees and Taxes	1,823,436	1,293,194	3,866,945	3,830,982
Share-Based Compensation	2,113,676	722,802	2,977,361	2,370,111
Deal Costs	0	1,174,357	429,272	2,811,944
Other General and Administrative	2,709,471	5,583,195	5,551,538	10,312,715
Total General and Administrative Expenses	$ 18,341,221	$ 31,292,754	$ 36,452,557	$ 63,941,988

OTHER OPERATING (INCOME) EXPE_3

OTHER OPERATING (INCOME) EXPENSE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Other Operating Income Expense
Loss (Gain) on Disposals of Assets	$ 1,153,225	$ (141,662)	$ 1,358,820	$ (126,516)
Restructuring and Reorganization Expense	0	385,652	423,793	2,764,327
Gain on Settlement of Accounts Payable	215,659	0	141,022	(177,990)
(Gain) Loss on Lease Terminations	(1,877,298)	173,765	(3,464,947)	173,765
(Gain) Loss on Disposal of Assets Held for Sale	(112,225)	0	532,598	0
Legal Settlements	(3,491,431)	0	(3,491,431)	0
Other Income	(1,522,280)	213,216	(3,043,918)	196,413
Total Other Operating (Income) Expense	$ (5,634,350)	$ 630,971	$ (7,544,063)	$ 2,829,999

OTHER OPERATING (INCOME) EXPE_4

OTHER OPERATING (INCOME) EXPENSE - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Other Operating Income Expense
Sublease Income	$ 1,521,651	$ 1,444,234	$ 3,043,302	$ 1,444,234

PROVISION FOR INCOME TAXES AN_3

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Income Tax Disclosure [Abstract]
Loss from Continuing Operations Before Provision for Income Taxes	$ (14,025,468)	$ (16,355,274)	$ (32,673,967)	$ (42,826,906)
Provision for Income Tax Expense	$ (1,060,808)	$ 8,137,898	$ (6,752,886)	$ (11,554,010)
Effective Tax Rate	8%	(50.00%)	21%	27%

PROVISION FOR INCOME TAXES AN_4

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 24, 2022	Dec. 24, 2022	Jun. 25, 2022
Income Tax Disclosure [Abstract]
Canadian non-capital losses		$ 12,230,000
Canadian non-capital losses, tax effected		3,240,000
Share issuance cost		6,000,000
Share issuance cost, tax effected		1,620,000
Valuation allowance	$ 217,300,000	217,300,000
Unrecognized tax benefits	18,781,424	18,781,424
Net discrete tax expense	$ 407,993	$ 407,993
California
Tax Credit Carryforward [Line Items]
Operating losses			$ 22,000,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 24, 2022	Jul. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Litigation amount claimed		$ 600
Litigation gain contingency, unrecorded		$ 18,500
Litigation settlement, expense	$ 350

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) $ in Thousands	6 Months Ended
	Dec. 24, 2022 USD ($)
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Periodic payment in cash	33.33%
Periodic payment in subordinated voting shares	66.67%
Board of Directors
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Directors' fees, periodic payment	$ 200

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details)	6 Months Ended
	Dec. 24, 2022
Segment Reporting [Abstract]
Number of operating segments	1

REVENUE (Details)

REVENUE (Details)	3 Months Ended		6 Months Ended
	Dec. 24, 2022 USD ($)	Dec. 25, 2021 USD ($)	Dec. 24, 2022 USD ($)	Dec. 25, 2021 USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments			1
Financing Receivable, Past Due [Line Items]
Revenue from Continuing Operations	$ 29,548,370	$ 35,517,161	$ 59,592,423	$ 72,253,065
Revenue from Discontinued Operations	2,282,288	8,065,341	5,911,927	15,405,440
Total Revenue	31,830,658	43,582,502	65,504,350	87,658,505
California
Financing Receivable, Past Due [Line Items]
Total Revenue	19,575,393	23,368,439	39,504,378	47,994,994
Nevada
Financing Receivable, Past Due [Line Items]
Total Revenue	2,812,902	3,855,371	5,810,371	7,934,522
Illinois
Financing Receivable, Past Due [Line Items]
Total Revenue	3,082,089	4,104,970	6,624,159	8,433,572
Arizona
Financing Receivable, Past Due [Line Items]
Total Revenue	3,343,592	4,173,609	6,138,238	7,875,206
Massachusetts
Financing Receivable, Past Due [Line Items]
Total Revenue	$ 734,394	$ 14,772	$ 1,515,277	$ 14,771

DISCONTINUED OPERATIONS - Narra

DISCONTINUED OPERATIONS - Narrative (Details) - USD ($)			3 Months Ended	6 Months Ended
	Sep. 15, 2022	Aug. 22, 2022	Dec. 24, 2022	Dec. 24, 2022
Discontinued Operations and Disposal Groups [Abstract]
Sales Price		$ 67,000,000
Sales in cash		63,000,000
Liabilities assumed by buyer		4,000,000
Proceeds from sale of assets	$ 11,500,000	40,000,000
Remains due and receivable			$ 11,500,000	$ 11,500,000
Proceeds from other debt		31,599,999
Proceeds from loan issuance		$ 19,558,947
Gain on sale of assets			$ 31,719,833	$ 31,719,833

DISCONTINUED OPERATIONS - Sched

DISCONTINUED OPERATIONS - Schedule of Net Operating Loss of Discontinued Operation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 24, 2022	Dec. 25, 2021	Dec. 24, 2022	Dec. 25, 2021
Discontinued Operations and Disposal Groups [Abstract]
Revenue	$ 2,282,288	$ 8,065,341	$ 5,911,927	$ 15,405,440
Cost of Goods Sold	439,466	5,672,043	2,630,135	10,899,596
Gross Profit	1,842,822	2,393,298	3,281,792	4,505,844
Expenses:
General and Administrative	2,134,342	6,329,144	6,853,135	11,946,739
Sales and Marketing	15,015	127,844	58,326	231,647
Depreciation and Amortization	21,107	1,189,331	894,002	2,411,090
Impairment Expense	0	0	(78,433)	0
Gain on Disposal of Assets and Other Income	0	0	(36,305,166)	(597,591)
Total (Income) Expenses	2,170,464	7,646,319	(28,578,136)	13,991,885
Income (Loss) from Discontinued Operations	(327,642)	(5,253,021)	31,859,928	(9,486,041)
Other Expense:
Interest Expense	1,783,685	4,755,126	5,545,446	9,371,955
Accretion of Debt Discount and Loan Origination Fees	0	3,446,949	398,032	6,987,857
Total Other Expense	1,783,685	8,202,075	5,943,478	16,359,812
Income (Loss) from Discontinued Operations Before Provision for Income Taxes	(2,111,327)	(13,455,096)	25,916,450	(25,845,853)
Provision for Income Tax Benefit (Expense)	(144,651)	1,314,496	216,039	(741,238)
Net Income (Loss) from Discontinued Operations	$ (2,255,978)	$ (12,140,600)	$ 26,132,489	$ (26,587,091)

DISCONTINUED OPERATIONS - Sch_2

DISCONTINUED OPERATIONS - Schedule of Assets Included in Discontinued Operation (Details) - USD ($)	Dec. 24, 2022	Jun. 25, 2022
Carrying Amounts of the Assets Included in Discontinued Operations:
Cash and Cash Equivalents	$ 540,828	$ 1,124,076
Restricted Cash	5,280	5,280
Accounts Receivable and Prepaid Expenses	22,019	334,621
Inventory	4,483,051	6,866,833
TOTAL CURRENT ASSETS
Property and Equipment, Net	9,569,610	41,273,597
Operating Lease Right-of-Use Assets	19,111,359	31,543,058
Intangible Assets, Net	10,582,559	40,799,146
Other Assets	458,383	1,181,795
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE	44,773,089	123,128,406
Carrying Amounts of the Liabilities Included in Discontinued Operations:
Accounts Payable and Accrued Liabilities	979,864	6,295,745
Income Taxes Payable	389,677	1,671,380
Other Current Liabilities	(5,641)	89,069
Current Portion of Operating Lease Liabilities	2,812,765	4,209,512
Current Portion of Finance Lease Liabilities	0	174,000
TOTAL CURRENT LIABILITIES
Operating Lease Liabilities, Net of Current Portion	18,398,345	56,410,071
Deferred Tax Liabilities	5,977,580	6,097,597
Notes Payable	0	11,100,000
TOTAL NON-CURRENT LIABILITIES
TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE	$ 28,552,590	$ 86,047,374